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Executive Summary
Routine vaccination in the United States is widely 
viewed as one of the greatest public health 
achievements of the past century. Despite this 
success, an increasing number of parents have 
been expressing concerns about vaccine safety 
over the last two decades. Parental vaccine 
worries have traditionally focused on specific 
vaccines, ingredients and types of adverse 
events. More recently, parents have been voicing 
concerns about the safety of the recommended 
immunization schedule as a whole, with opinions 
that children receive too many vaccines at 
too young of an age, and that early childhood 
immunization overwhelms the immune system. 
These sentiments reflect the number, frequency 
and timing of recommended vaccines, leading 
some parents to refuse or delay vaccinations for 
their children. 
In response to these concerns, the Institute of 
Medicine (IOM) in 2012 convened a committee 
to gather stakeholder input and scientific 
evidence on the safety of the recommended 
childhood immunization schedule.1 The committee 
concluded that, while available evidence 
indicated that the current U.S. immunization 
schedule was safe, few published investigations 
had specifically examined the safety of the 
recommended childhood schedule as a whole. 
The committee recommended that additional 
observational studies of the safety of the schedule 
were warranted, and stated that the Vaccine Safety 
Datalink (VSD) project2 represents one of the 
best resources in the nation for conducting such 
studies. The VSD is an established collaboration of 
nine managed care organizations (MCOs) where 
electronic health record (EHR) data on over 9 
million people are used to conduct observational 
studies on vaccine safety.
The IOM report also highlighted four research 
questions of highest priority to stakeholders: 1) 
how do child health outcomes compare between 
fully vaccinated and unvaccinated children; 2) 
how do child health outcomes compare between 
fully vaccinated children and children whose 
parents have refused specific vaccines; 3) do 
short- and long-term health outcomes differ when 
comparing children vaccinated according to the 
recommended schedule to children receiving 
fewer vaccines per visit or receiving vaccines 
at later ages; and 4) are some subpopulations 
of children at increased risk of adverse events 
following immunization (for example, children 
with a family history of allergic or autoimmune 
disease).
To address these research questions, the IOM 
report emphasized the need to carefully consider 
the potential impact of confounding and bias. In 
particular, the committee stressed that decisions 
to initiate future safety studies should include an 
assessment of the following: 1) epidemiological 
evidence of adverse events; 2) biologic plausibility 
of associations between the immunization 
schedule and adverse events of interest; and 3) 
stakeholder concerns about the safety of the 
schedule. 
Guided by the IOM committee’s assessment of 
the unique and important role the VSD could play 
in this area of study, the Immunization Safety 
Office (ISO) of the Centers for Disease Control 
and Prevention (CDC) issued a request for a White 
Paper. The focus of the White Paper was to be 
determine how the VSD could be used to study 
the safety of the entire childhood immunization 
schedule. 
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The White Paper had the following four 
objectives:
Four objectives of White Paper:
1. Define types of alternative immunization 
schedules and patterns of undervaccination 
that could be evaluated, focusing on the first 
24 months of age
2. Identify plausible adverse event outcomes 
that could be related to the childhood 
immunization schedule, with an emphasis on 
long-term adverse events
3. Suggest methodological approaches that 
could be used to assess the safety of the 
recommended schedule as a whole
4. Propose next steps for studying the safety of 
the childhood immunization schedule within 
the VSD 
The document was developed and written 
between September 2013 and December 2014. 
All funding for the project was obtained through 
a CDC VSD contract. No funding was provided 
by pharmaceutical companies or other sources. 
The White Paper study team had no conflicts of 
interest to declare. 
Three separate but related content areas were 
addressed: defining exposure to different 
immunization schedules, identifying health 
outcomes to study in the context of the 
immunization schedule, and describing 
epidemiological and statistical methods to study 
the safety of the schedule. The study team first 
reviewed the IOM report in detail and conducted 
a review of published literature. Two in-person 
meetings with subject matter experts (SME) were 
then held. The first meeting occurred in February 
2014 in Atlanta, Georgia, with three internationally 
regarded vaccinologists: Drs. Walter Orenstein, 
Stanley Plotkin and Edgar Marcuse. The second 
meeting was in June 2014 in Seattle, Washington, 
with two expert statisticians: Drs. Martin Kulldorff 
and M. Alan Brookhart. These meetings were audio 
recorded and transcripts were analyzed to identify 
key themes to guide the final report.
Next, we summarize each of the three main 
content areas in the White Paper.
Exposure: Defining patterns of under-
vaccination and alternative immunizations 
schedules (Chapter 2) 
The objective of this chapter was to describe 
various approaches for using VSD databases 
to create cohorts of undervaccinated children 
for future safety studies of the recommended 
immunization schedule. Undervaccination is 
broadly defined as children who are either behind 
on their immunizations or on an immunization 
schedule that differs from the recommended 
schedule of the Advisory Committee on 
Immunization Practices (i.e., an alternative 
immunization schedule).3,4 In theory, the safety of 
the recommended immunization schedule could 
be evaluated by comparing rates of adverse events 
between cohorts of undervaccinated children and 
children who are age-appropriately vaccinated. As 
shown in prior VSD research, however, defining 
these cohorts poses numerous methodological 
challenges that could threaten the validity of 
future safety studies, including information bias, 
confounding and lack of statistical power.3 
To help address these challenges, chapter two 
describes a four staged approach for creating 
cohorts of undervaccinated children for safety 
studies. Within each stage, there are several 
suggested methods that investigators can consider 
when designing future studies.
In Stage 1, different methodological approaches 
for identifying a cohort of undervaccinated 
children are presented. After a cohort of 
undervaccinated children has been identified, 
children can be further grouped by different 
patterns of undervaccination. Stage 2 provides 
details on 11 different methods for characterizing 
patterns of undervaccination, including using the 
VSD databases to identify published alternative 
schedules, shot limiting, delayed start to 
vaccination, vaccine series not received, spacing 
of vaccines, order of vaccines, and exposure to 
vaccine components such as antigen and non-
antigen vaccine ingredients. 
Stage 3 describes approaches to address issues 
arising with small sample sizes, misclassification 
and confounding. For small sample size 
concerns, a data mining analytic approach for 
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creating groupings of undervaccinated children 
is proposed. To address misclassification of 
vaccination data, a method using an International 
Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) code specific 
for vaccine refusal is presented. Lastly, there is 
a description of how VSD health care utilization 
data can be used to help address confounding and 
misclassification of vaccination and outcome data. 
After groups of undervaccination have been 
identified, health care utilization behaviors and 
the potential for missing vaccination data can be 
further evaluated through primary data collection. 
Stage 4 describes two methods of data collection: 
manual medical record review and surveys with 
parents. These approaches can be used to confirm 
vaccination status, to determine if reasons for 
undervaccination are due to parental refusal or 
delay, and to assess whether the child is receiving 
care outside of the MCO, which may lead to 
misclassification of outcome status if an adverse 
event occurs.
Outcomes: plausible adverse events 
that could be studied relative to the 
entire childhood immunization schedule 
(Chapter 3) 
In addition to identifying meaningful exposure 
groups of undervaccination and alternative 
schedules, the IOM’s 2013 report stressed the 
importance of identifying plausible health 
outcomes that could be evaluated in the context 
of the immunization schedule as a whole.1 While 
the IOM report did not rule out short-term acute 
events, it stressed the importance of studying 
longer-term outcomes, such as autoimmune 
diseases, asthma and other allergic conditions. 
The following three-phased approach was used to 
identify, categorize and prioritize such outcomes 
for future safety studies in the VSD: 
1. Generate a list of potential outcomes
2. Subject matter expert (SME) engagement
3. Final prioritization
In Phase 1, the study team conducted a review 
of the medical literature, and three IOM reports 
from 2002, 2011 and 20131,58,62 to generate a list 
of 75 potential outcomes. The outcomes were first 
organized by system/organ type (e.g., respiratory 
system, neurological system) or reaction type 
(e.g., allergy, anaphylaxis). The study team 
then summarized and reviewed the available 
evidence related to biological and mechanistic 
plausibility, and appropriateness of evaluating 
the adverse event in the context of the childhood 
immunization schedule. After internal discussion 
among the study team using these criteria, the list 
was reduced to 47 plausible outcomes.
In Phase 2, the list of 47 outcomes was presented 
to the three vaccine science SMEs to gain 
additional insight into the appropriateness of 
studying specific outcomes in the context of the 
childhood immunization schedule and to conduct 
an initial prioritization of the outcomes. The SMEs 
concluded that four diseases could be excluded 
because they either rarely occur during childhood 
or are extremely rare in the general population. 
After lengthy discussion, the SMEs made several 
suggestions for the remaining 43 outcomes. They 
first stressed the importance of identifying long-
term outcomes with clear diagnostic criteria, 
such as those having a definitive diagnostic test 
result or when case status could be confirmed 
using manual medical record review. Second, the 
SMEs expressed the need to strongly consider 
public concern when deciding on outcomes to 
study; in certain instances, they said that public 
concern may be a more important consideration 
than biologic plausibility. The SMEs were also 
concerned that many of the outcomes may be 
too rare to study. They requested additional 
age-specific incidence data on the outcomes and 
suggested that several of the outcomes could 
be grouped together. For example, the SMEs 
recommended that a single outcome grouping 
called “first demyelinating events” could include 
acute disseminated encephalomyelitis, chronic 
inflammatory demyelinating polyneuropathy, 
Guillain-Barre syndrome, neuromyelitis optica, 
optic neuritis, and transverse myelitis. The 
meeting concluded with an aggregation exercise 
in which study team and SMEs reduced the list 
of 43 outcomes to an initial list of 31 prioritized 
outcomes. 
Following the SME meeting, the study team 
conducted a final prioritization of the 31 outcomes 
(Phase 3). In this last phase, the VSD databases 
were first used to calculate incidence rates of 
diagnosis for each outcome among children ages 
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3–8 years. The study team then reviewed the 
incidence estimates and classified each outcome 
as being either feasible or not feasible to study in 
the VSD; a rate of 5 diagnosed cases per 100,000 
person-years was used as a cut-off for feasibility. 
This step eliminated 11 of the 31 outcomes as 
being too rare to study in the VSD. 
After determining feasibility, the study team 
ranked the remaining 20 outcomes on public 
health significance and public health concern. 
The study team considered the seriousness of the 
condition, the rarity of the condition, whether 
the condition was increasing in prevalence, 
whether the outcome has already been studied 
as an adverse event, and whether vaccine 
hesitant parents would associate the outcome 
with vaccination. Using these criteria, team 
members ranked each of the outcomes on a 1–5 
scale for public health significance and public 
health concern, with a ranking of 5 representing 
the highest priority. The two scores were then 
averaged across the study team and summed 
together, resulting in a combined score between 2 
and 10 for each outcome. 
To conclude Phase 3, the final rankings were 
reviewed and discussed by the study team. In 
these discussions, team members could make 
the case to move outcomes up, down or off the 
priority list. A final list of ranked outcomes is 
presented here:
Ranking of outcomes based on feasibility, public health significance, 
and public concern 
1. Asthma
2. Anaphylaxis
3. Encephalopathy
4. All-cause mortality
5. Meningitis
6. Learning, communication and 
developmental disorders
7. Epilepsy
8. Type 1 diabetes
9. First demyelinating event
10. Allergy development
11. Attention deficit disorder
12. All-cause morbidity
13. Crohn’s disease and ulcerative colitis
14. Syncope and vasovagal reaction
15. Seizures
16. Kawasaki disease
17. Juvenile rheumatoid arthritis
18. Tics
19. Chronic urticaria
20. Bell’s palsy
Methods: Study designs and statistical 
analyses to study the safety of the 
schedule (Chapter 4)
On June 27, 2014, the study team met with 
VSD staff and external experts on drug and 
vaccine safety methodology. Several important 
methodological recommendations were developed 
from the meeting. First, investigations into the 
safety of the vaccine schedule should plan for 
multi-part studies. Initial studies can be used to 
identify possible associations between outcomes 
and various vaccine schedules. This will then 
lead to follow-up studies to verify the observed 
associations and identify which aspects of the 
schedule(s) are responsible for them. Second, 
because vaccine schedule research is a field in its 
infancy, initial studies of vaccine schedule safety 
should focus on designs and methods with well-
known properties – such as the cohort and case-
control methods – until the various sources of bias 
in schedule safety research are better understood. 
Examples of these potential sources of bias 
include unmeasured confounding, health care 
seeking bias, reverse causality, selection bias and 
misclassification of exposures and outcomes.
Chapter 4 describes several methods to help 
address these biases in safety studies of the 
schedule. For example, to identify potential 
confounding variables, causal models such as 
directed acyclic graphs (DAGs) may be used. 
These models allow the investigator to identify 
whether key confounders can be controlled for 
using existing VSD databases, whether additional 
data needs to be collected, or whether certain 
confounders are unmeasurable. Examples of 
potentially important confounding variables that 
are not routinely collected in the VSD databases 
are parental education, income, and family history 
of chronic illness. These factors may be associated 
with parental vaccine decisions and may require 
more labor-intensive data collection to measure.
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To evaluate the direct influence of uncontrolled 
confounding, initial safety studies should also 
include negative controls whenever possible. 
Negative control outcomes are conditions with 
no expected causal association with the vaccine 
schedule in infants and young children, such as 
fractures, sprains or other minor injuries. If a 
study finds an association between the vaccine 
schedule and a control outcome, it suggests 
that unmeasured confounding may be present. 
Potential remedies include collecting additional 
sociodemographic data, or to control for 
differences in health care utilization, since parents 
of undervaccinated children may be more or 
less likely to seek medical attention than parents 
who vaccinate according to the recommended 
schedule. 
In addition to confounding, information bias is a 
concern because vaccination status, outcomes and 
important covariates may be imperfectly measured 
in the VSD databases. Chapter 4 describes, in 
detail, how misclassification of these factors can 
lead to effect estimates that are biased either 
toward or away from the null. Several analytic 
methods to address these potential sources of 
information bias are also discussed, including the 
use of health care utilization data to match fully 
and partially vaccinated children, or to restrict 
the study population to children who have had 
a minimum amount of utilization (e.g., three 
outpatient visits) while enrolled in their respective 
MCO during the first year of life. 
Other approaches to address information bias 
involve quantifying the misclassification though 
primary data collection using cross-sectional 
surveys of parents and/or medical record review. 
For example, surveys on a sample of parents 
could be used to assess measurement error in 
vaccination history and/or to collect important 
covariates such as parental education or 
household income. After quantifying the degree 
of misclassification with primary data collection, 
sensitivity analyses using statistical simulation 
techniques could then be used to correct for the 
misclassification bias when estimating associations 
between the immunization schedule and outcomes 
of interest.
The chapter concludes with an example of a study 
to evaluate the association between a known 
immunization schedule and the risk of asthma. 
The example illustrates all phases of the study, 
including defining the study population, exposure 
groups, outcomes, covariates and analytic 
approaches. 
Summary 
This White Paper provides a comprehensive 
assessment for how the VSD could be used to 
study the safety of the recommended childhood 
immunization schedule. Guided by subject matter 
expert engagement, the document outlines a 4 
staged approach for identifying exposure groups 
of undervaccinated children, presents a list of 20 
prioritized outcomes, and describes various study 
designs and statistical methods that could be 
used to analyze the safety of the schedule. VSD 
investigators will be able to use this document as 
a guide when designing and conducting studies 
of the safety of the childhood immunization 
schedule, if such studies are judged to be 
necessary.
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Chapter 1: Introduction
1.1 Significance
1.2 IOM Report on the Childhood Immunization Schedule and Safety
1.3 Objectives of White Paper
1.4 Process of Developing White Paper
1.5 Studying the Safety of the Childhood Immunization Schedule: 
Defining Key Concepts
1.6 Organization of the White Paper Report
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1.1 Significance
Routine vaccination in the U.S. has prevented 
millions of serious illnesses and deaths,5-7 and 
vaccination is widely viewed as one of the 
greatest public health achievements of the past 
century.8 Maintaining high vaccination coverage 
within the population is critical to the ongoing 
effort to prevent a wide array of vaccine-
preventable diseases. While vaccination rates for 
young children in the U.S. are high relative to 
historical benchmarks9,10 an increasing number of 
parents have expressed concerns about the safety 
of vaccines in the past two decades. Some of these 
concerned parents are choosing to refuse or delay 
vaccines for their children.11-14 Vaccine refusal and 
delay has contributed, in turn, to the spread of 
vaccine-preventable diseases in the community.15-18 
The nature of parent concerns about vaccine 
safety is complex and fluid, with concerns 
varying widely between parents and over time.11-
14 Some parents have voiced concerns about 
specific vaccines (e.g., measles-mumps-rubella 
[MMR]), vaccine ingredients (e.g., thimerosal 
and aluminum), and the development of 
certain medical conditions (e.g., autism). More 
recently some parents have stated that little is 
known about the safety of the recommended 
immunization schedule as a whole. Some parents 
have expressed the opinion, for example, that too 
many vaccines are given to children at too young 
of an age and that early childhood immunization 
overwhelms the immune system. These sentiments 
reflect concern about the number, frequency, 
and timing of recommended vaccines rather 
than about the specific properties of particular 
vaccines.14,19-21 
The immunization schedule for the U.S. is 
established by the Advisory Committee on 
Immunization Practices (ACIP). In fact “the 
schedule” is a term used to encompass an 
extensive set of immunization recommendations 
guiding immunization delivery from birth 
through old age.22,23 The schedule sets forth at 
what age particular vaccines should be given, 
with recommendations based upon a number 
of considerations, including disease burden, 
age at disease onset and peak incidence, 
immunogenicity, reactogenicity, and other 
practical considerations. Many more vaccines are 
recommended before 24 months of age than at 
any other age,22,23 and parents appear particularly 
concerned about the safety of vaccines given to 
young children.11-14 
1.2 IOM Report on the Childhood 
Immunization Schedule and Safety
In response to this public concern, the Institute 
of Medicine (IOM) in 2012 convened a 
committee to examine scientific evidence and 
stakeholder concerns regarding the safety of the 
recommended childhood immunization schedule, 
and to identify study designs and methods that 
could be used to rigorously examine this issue1. 
The IOM committee concluded that while the 
accumulation of available evidence indicated 
that the current U.S. immunization schedule was 
safe, few published investigations had specifically 
evaluated the safety of the childhood schedule 
as a whole. The committee concluded that new 
observational studies of the safety of the schedule 
were warranted, and stated that the Vaccine Safety 
Datalink (VSD) project2 represented one of the best 
resources in the nation for conducting such studies.
The IOM report also highlighted four research 
questions of highest priority to stakeholders: 1) 
how do child health outcomes compare between 
fully vaccinated and unvaccinated children; 2) how 
do child health outcomes compare between fully 
vaccinated children and children whose parents 
have refused specific vaccines; 3) do short- and 
long-term health outcomes differ comparing 
children vaccinated according to the recommended 
schedule to those receiving fewer vaccines per 
visit or receiving vaccines at later ages; and 4) are 
some subpopulations of children at increased risk 
of adverse events following immunization (for 
example, children with a family history of allergic 
or autoimmune disease).1
Although the IOM committee endorsed the need 
for and importance of studies of the safety of 
the schedule, the IOM report also emphasized 
the complexities of such studies, and the need to 
carefully consider issues of confounding and bias. 
In light of these considerations, the committee 
cautioned that decisions related to initiating 
further studies of the schedule should include an 
assessment of the following: 1) the epidemiological 
evidence of a potential adverse event related to 
the childhood immunization schedule; 2) the 
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biological plausibility of the association between an 
adverse event and the schedule; and 3) stakeholder 
concerns about the safety of the schedule. In this 
context, stakeholder concerns would prompt an 
examination of the epidemiological evidence and 
biological plausibility related to a particular adverse 
event of concern1.
1.3 Objectives of White Paper
Guided by the IOM committee’s assessment of 
the unique and important role the VSD could play 
in this area of study, the Immunization Safety 
Office (ISO) of the Centers for Disease Control 
and Prevention (CDC) issued a request for a 
White Paper, to focus on how the VSD could be 
used to study the safety of the entire childhood 
immunization schedule. The White Paper had the 
four following objectives:
1. Define types of alternative immunization 
schedules and patterns of undervaccination 
that could be evaluated;
2. Identify plausible adverse event outcomes 
that could be related to the childhood 
immunization schedule;
3. Suggest methodological approaches that 
could be used to assess the safety of the 
recommended schedule as a whole; and
4. Propose next steps for studying the safety of 
the childhood immunization schedule within 
the VSD.
1.4 Process of Developing White Paper
The White Paper was designed and written between 
September 2013 and December 2014. All funding 
for the White Paper came from the CDC, through 
the contract for participation in the VSD project. No 
funding was provided from any other sources. The 
team of collaborators involved in developing the 
White Paper is listed in the preface material. None 
of the White Paper study team members had any 
relevant conflicts of interest to declare. The protocol 
for completing the White Paper was submitted 
to the institutional review board (IRB) at Kaiser 
Permanente Colorado, and was deemed not to 
constitute human subjects research.
Initially, the study team reviewed the IOM 
report in detail. Although other published 
literature was also reviewed in detail, we did not 
conduct a formal literature review, because a 
comprehensive literature search and review was 
recently conducted as a part of the IOM committee 
information gathering process.
The work of the White Paper was divided into 
three separate but related content areas: defining 
exposure to different immunization schedules; 
defining health outcomes that could be studied in 
the context of the entire immunization schedule; 
and developing methods to study the safety of 
the schedule. For each content area, an iterative 
approach was taken, with the development of 
initial strategies and challenges, presentation of 
this material to subject matter experts (SMEs), and 
revision of the content based upon feedback from 
SMEs.
Engagement with SMEs was conducted 
primarily through two in-person meetings. In 
February 2014, at Emory University in Atlanta, 
Georgia, an all-day meeting was held with 
three vaccinologists: Drs. Walter Orenstein, 
Stanley Plotkin, and Edgar Marcuse. These three 
individuals are internationally regarded experts 
in the area of vaccine science. In June 2014, a 
meeting was held in Seattle, Washington with 
Drs. Martin Kulldorff and M. Alan Brookhart, two 
individuals with particular expertise in the areas 
of research methods and statistical analyses.
At each of the in-person SME engagement 
meetings, the discussion was audio-recorded and 
later professionally transcribed. The study team 
also kept detailed paper notes of the discussion. 
After the meetings, the transcript and paper notes 
were reviewed by the study team to identify the 
key themes emerging from the meeting. The team 
then met as a group to review and refine key 
themes through an iterative process.
As will be described later in this report, one of 
the themes to emerge from SME engagement was 
that evaluating the feasibility of studying specific 
health outcomes was dependent upon knowledge 
of how common or rare these outcomes were in 
the VSD population. Because of this feedback, as 
part of the White Paper process we used the VSD 
databases to calculate crude incidence rates of 
diagnoses for health outcomes of interest. 
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1.5 Studying the Safety of the 
Childhood Immunization Schedule: 
Defining Key Concepts
The Immunization Schedule
The IOM committee acknowledged that, in order 
to study the safety of the childhood immunization 
schedule, more clarity was needed about what 
defines the schedule. The U.S. immunization 
schedule, established by the ACIP, is an extensive 
set of immunization recommendations guiding 
immunization delivery from birth through old 
age.22,23 The immunization schedule changes 
over time, as new vaccines are licensed, or the 
recommendations for existing vaccines change 
based on new knowledge. In addition, for some 
vaccines, the immunization schedule allows for a 
relatively wide age interval within which vaccines 
can be delivered (e.g. the third dose of inactivated 
poliovirus vaccine [IPV] is recommended to be 
administered between 6 and 18 months of age).23 
Finally, the schedule also allows for the use of 
different vaccine products with different dosing 
schedules (e.g. there are two different rotavirus 
vaccines currently licensed in the U.S., one which 
requires two doses and another which requires 
three doses).
For the purposes of the White Paper, we chose 
to focus on the schedule of vaccines routinely 
recommended for infants and young children 
before 24 months of age. The rationale for this 
decision is as follows. First, more vaccines are 
recommended before 24 months of age than at 
any other time of life, with multiple doses of 
particular vaccines recommended. Second, parents 
appear to be more concerned about the safety 
of the schedule (i.e. the timing and spacing of 
multiple vaccines) for young children rather than 
for older children and adults.11-14 Third, several 
of the medical conditions of concern to parents, 
such as asthma and allergic disorders, may become 
apparent clinically in the pre-school age group, 
roughly corresponding to 2 to 6 years of age. 
Finally, long periods of time elapse between the 
infant immunization series, the “school entry” series 
at 4 to 6 years of age, and the “pre-teenager” series 
at 11 years of age; these long time periods create 
conceptual as well as methodological uncertainty 
about what would define the schedule in later 
childhood and how it could be evaluated. 
Safety
For the White Paper, we chose to explicitly define 
safety as the absence of vaccine-associated adverse 
events following immunization. Parental vaccine 
delay or refusal leads to an increased risk of 
vaccine-preventable disease in children,16-18 and 
safety could be defined more broadly to include 
the prevention of disease. However, considerations 
related to vaccine effectiveness, and the risks 
associated with vaccine refusal, were considered 
out of scope of this White Paper. Nonetheless, any 
new knowledge generated about adverse events 
related to the immunization schedule could be 
used in the future by national policy makers when 
weighing all available evidence about the benefits 
and risks of vaccination.
Focus on Long-term Outcomes
While there is not a uniform definition of what 
constitutes a short- versus long-term adverse 
event, short-term adverse events are typically 
thought to occur in the hours, days, or weeks 
following vaccination. For example, VSD studies 
of vaccine safety will generally evaluate adverse 
events in the 1-2, 1-7, 1-14, or 1-42 days following 
vaccination. Long-term outcomes can be thought 
of as occurring in the months to years following 
vaccination.
After stakeholder engagement and a review of 
existing literature, the IOM committee concluded 
that while both short- and long-term adverse events 
were important, the study of long-term outcomes 
following the routine schedule was a higher priority. 
The current safety surveillance systems such as the 
VSD,2 and the Post-Licensure Rapid Immunization 
Safety Monitoring (PRISM)24 system of the Food and 
Drug Administration (FDA), already have extensive 
systems in place to assess short-term outcomes. 
Parents have expressed more concerns about 
long-term than short-term health outcomes, and 
have argued that long-term health outcomes have 
been less well-studied in the context of vaccine 
safety. Finally, because the childhood immunization 
schedule is essentially a long-term exposure, 
occurring over 18 to 24 months, long-term adverse 
events may be more biologically plausible than 
short-term events. Therefore, for the purposes of the 
White Paper we chose to focus primarily on long-
term adverse events. 
VSD White Paper | Safety of the Childhood Vaccination Schedule 10
Summary
In summary, the following key decisions and 
concepts guided the work of the White Paper:
• The schedule was defined as those vaccines 
routinely recommended for children prior to 
24 months of age;
• Safety was defined as the relative absence of 
adverse events following immunization; and
• Long-term adverse events were viewed as the 
primary area of focus, as opposed to more 
acute events following immunization.
1.6 Organization of the White Paper 
Report
The White Paper is organized into 5 chapters 
and 5 appendices. The first, introductory chapter, 
presented a brief background, describes the 
objectives of the White Paper, and introduces 
several key concepts and decision points. The 
second chapter defines the types of alternative 
immunization schedules and patterns of 
undervaccination that could be evaluated in 
safety studies. The third chapter identifies adverse 
event outcomes that could possibly be related 
to the childhood immunization schedule. The 
fourth chapter focuses on the methodological 
approaches that could be used to assess the safety 
of the recommended schedule as a whole. The 
final chapter presents a summary of the findings 
of the White Paper, addresses limitations to the 
methods and scope of the White Paper, and 
proposes several recommended next steps that 
should be considered when evaluatong the safety 
of the recommended childhood immunization 
schedule. 
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Chapter 2: Exposure
2.1 Introduction
2.2 Summary of methods subject matter expert meeting
2.3 Prior work on undervaccination in VSD
2.4 Staged approach for identifying patterns of undervaccination and 
assessing misclassification
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2.1 Introduction
In this chapter, we describe various approaches 
for how the VSD can be used to create cohorts 
of undervaccinated children. Undervaccination is 
broadly defined as children who are either behind 
on their immunizations or on an immunization 
schedule that differs from the recommended 
schedule of the ACIP (i.e., an alternative 
immunization schedule). Accurately identifying 
undervaccinated children in the VSD can be 
quite challenging. While numerous studies have 
confirmed the validity of electronic vaccination 
data compared to vaccination data from manual 
medical record review,25-27 the validity of missing 
pediatric vaccination records in the VSD is 
currently not known. In other words, if a child has 
electronic vaccination records in VSD databases, 
there is a high likelihood that the child actually 
received those vaccines. However, if the child 
appears undervaccinated in the databases, the 
lack of vaccination may be attributed to several 
causes. One cause is actual vaccine delay, which 
can be intentional or unintentional. Parents may 
consciously refuse or delay vaccines for their 
children, while other families may be experiencing 
barriers to care. In both instances, these children 
would be considered undervaccinated. In contrast, 
lack of vaccination records in the EHR may also 
be due to missing immunization records, which 
can occur when children have gaps in managed 
care organization (MCO) enrollment or when 
they are receiving vaccines outside of the MCO. 
These children would be misclassified as being 
undervaccinated. Minimizing such misclassification 
of vaccination status is particularly important 
because it can threaten the validity of future safety 
studies of the schedule. 
We begin the chapter with a description of prior 
research on undervaccination in the VSD, and 
then suggest a staged approach by which cohorts 
of undervaccinated children can be identified and 
verified using the VSD databases and primary 
data collection. The overall goal of this staged 
approach is to identify groups of undervaccinated 
children that could be included in safety studies 
with minimal bias from misclassification and 
confounding.
2.2 Summary of methods subject 
matter expert meeting
On June 27th, 2014, Group Health Research 
Institute hosted a meeting of VSD collaborators 
and outside experts in drug safety methodology. 
The meeting’s objectives were to elicit 
recommendations from the outside experts on 
analytic approaches for assessing the safety of the 
childhood immunization schedule. The outside 
experts were Martin Kulldorff, of Harvard Medical 
School, and M. Alan Brookhart of the University 
of North Carolina. The experts made several 
recommendations on study designs, statistical 
approaches, methods to address confounding 
and bias, and approaches for defining patterns 
and categories of undervaccination. In this 
chapter, we incorporate their recommendations 
for defining undervaccination patterns; their 
other recommendations are addressed in the 
fourth chapter on methodological approaches for 
studying the safety of the schedule. 
2.3 Prior work on undervaccination in 
VSD
The VSD recently conducted a population-
based cohort study of undervaccination,3 the 
results of which were presented to the IOM 
committee assessing the safety of the childhood 
immunization schedule. The objective of this 
feasibility study was to examine patterns and 
trends of undervaccination and alternative 
vaccination schedules to inform future studies 
of the safety of the recommended childhood 
immunization schedule.
The VSD databases were first used to identify a 
cohort of 323,247 children enrolled from birth 
to 24 months of age. In this large cohort, the 
average number of days undervaccinated (ADU) 
was calculated for each child. ADU is a continuous 
metric that quantifies immunization status over 
the first two years of life (details of how ADU is 
calculated are described in section 2.4 below). 
In brief, ADU measures the difference in time 
between when a child actually received his or her 
vaccines and when the vaccines should have been 
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received according to the ACIP recommended 
schedule, allowing for a grace period. At two 
years of age, children who are age-appropriately 
vaccinated have an ADU = 0, while completely 
unvaccinated children have an ADU = 479 days 
(Appendix 2.a). 
After calculating ADU, the cohort was divided into 
two groups: children who were undervaccinated 
for at least one day and children who were 
age-appropriately vaccinated. Undervaccinated 
children were further categorized according to 
whether or not they received an ICD-9 code for 
parental vaccine refusal (V64.05, V64.06), or if 
they were on a known alternative immunization 
schedule (Table 2.a). A medical record review 
was then conducted to better understand the 
reasons for undervaccination and to assess 
the potential for missing immunization data. 
Separate medical record reviews were conducted 
for undervaccinated children with and without 
an ICD-9 code for vaccine refusal. For the 
medical record reviews, abstractors looked for 
documentation that the parents had explicitly 
delayed or refused vaccines for their children. 
Lastly, a matched cohort analysis compared health 
care utilization rates between undervaccinated 
and age-appropriately vaccinated children.
Table 2.a: Specific alternative schedules previously 
identified in VSD data3,28,30
• No vaccines before age 24 months 
• No hepatitis B, polio, MMR, or varicella 
vaccines before age 24 months, but other 
vaccines received (consistent with the 
Selective Schedule in The Vaccine Book by 
Dr. Robert Sears)28
• First 3 doses of Hib and pneumococcal 
vaccines given on the same day, but on a 
different day than the first 3 doses of DTaP 
(consistent with the Alternative Schedule in 
The Vaccine Book by Dr. Robert Sears)28
• Delaying start to vaccination until 4, 6 or 
12 months of age
• Consistent shot-limiting: limiting 
vaccinations per visit to 2 or fewer
The results from this study3 showed that 48.7% 
(n=157,454) of the cohort was undervaccinated 
for at least one day before age 2 years, while only 
1.9% (n=6,172) had an ICD-9 code for vaccine 
refusal and only 2.8% (n=8,939) were identified 
as being on a known alternative immunization 
schedule. In the overall cohort of undervaccinated 
children, distinct patterns of undervaccination 
were identified by categorizing each of eight 
childhood vaccines into one of three groups: all 
doses received on-time, no doses received, or 
some doses either missing or not received on-
time. With this method, 1399 different patterns of 
undervaccination and alternative immunization 
schedules were identified. Among children with 
an ICD-9 code for vaccine refusal, there were 756 
different patterns of undervaccination. Since these 
patterns only considered three broad categories 
for each vaccine, this calculation did not consider 
other factors related to the schedule such as the 
age, spacing, or order of vaccinations. Considering 
these other factors could result in millions of 
different combinations of vaccination patterns, 
which presents potential challenges in identifying 
clinically meaningful cohorts for future safety 
studies. 
The medical record review among undervaccinated 
children without an ICD-9 code for vaccine refusal 
showed that reasons for undervaccination were 
only present in 40% of records, thus highlighting 
the potential for misclassification due to missing 
information. In contrast, the medical record review 
among undervaccinated children with an ICD-9 
code showed a high confirmation rate of 94% for 
parental vaccine refusal. It is therefore likely the 
immunization data for these latter children were 
accurately captured, implying that they could be 
included in safety studies with minimal exposure 
misclassification.
Lastly, the matched cohort analysis showed 
differences in rates of health care utilization 
between age-appropriately vaccinated and 
undervaccinated children. Undervaccinated 
children had lower rates of outpatient utilization 
and higher rates of inpatient utilization compared 
to age-appropriately vaccinated children. 
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In summary, these results demonstrate that there 
are numerous methodological challenges to 
consider when creating undervaccinated cohorts 
to study the safety of the recommended schedule 
(Table 2.b). While undervaccination is common, 
there is a considerable amount of variability 
in vaccination patterns, as well as potential for 
missing vaccination data and bias from differences 
in health care seeking behaviors. Misclassification 
of vaccination status can be minimized among 
children with an ICD-9 code for vaccine refusal, 
but these children are small in number and could 
not be used to study uncommon outcomes in 
safety studies. Next we describe a four-staged 
approach to help address these methodological 
barriers.
Table 2.b: Summary of methodological challenges 
identified from previous VSD research on 
undervaccination
• Considerable variability in patterns of 
undervaccination
• Few children with an ICD-9 code 
indicating parental refusal of vaccination
• Potential for misclassification of 
vaccination status in electronic health 
record data 
• Potential for information bias and 
confounding from differences in health 
care seeking behavior between fully 
vaccinated and undervaccinated children
2.4  Staged approach for identifying 
patterns of undervaccination 
In this section, we describe a four staged 
approach for creating cohorts of undervaccinated 
children for future safety studies. Within each 
stage, we suggest several possible methods that 
VSD investigators can consider when designing 
their studies. In stage 1, we describe four different 
methods for identifying undervaccinated children. 
In stage 2, we suggest various methods by which 
undervaccinated children can be characterized 
and grouped. Once children have been grouped, 
stage 3 presents methods for addressing issues 
related to sample size, exposure misclassification 
and potential confounding. Lastly, stage 4 
describes approaches for collecting primary data 
on the groupings of undervaccinated children to 
further assess the potential for misclassification 
and confounding. 
Stage 1: Identify undervaccinated children
Described below are four different methods that 
can be used to identify undervaccinated children 
in the VSD cohort. We also briefly describe state 
immunization registry data, which have the 
potential to be combined with the electronic 
health record (EHR) data used in the VSD.
Days Undervaccinated 
Being age-appropriately vaccinated is based on 
the recommended schedule of the ACIP. The ACIP 
recommends that all healthy children receive their 
primary series of immunizations at birth, 2, 4, 6, 
12 –15, and 18 months of age.23 In 2005, Luman 
et al.,4 calculated the total days undervaccinated 
for 6 childhood vaccines in a large, nationally 
representative population of children ages 18-36 
months. Days undervaccinated is a metric that 
quantifies the number of calendar days a child is 
undervaccinated for any recommended vaccine.4 
For each vaccine, days undervaccinated is 
calculated by taking the difference between when 
each vaccine dose was administered and when 
the vaccine dose should have been administered 
according to the ACIP schedule. 
There is a grace period around ACIP’s 
recommended age for each vaccine dose. For 
example, ACIP recommends giving the first dose 
of diphtheria-tetanus-acellular pertussis (DTaP) 
vaccine at age 2 months; however, a child is not 
considered undervaccinated for DTaP unless he or 
she turns 3 months of age (age 93 days) without 
receiving the vaccine. That is, the count for 
undervaccination for the first dose of DTaP is not 
started until age 93 days. When calculating days 
undervaccinated, if a child is undervaccinated for 
more than one vaccine on a given day, that day is 
only counted once in the calculation (Figure 2.a). 
Full details on the criteria used to evaluate days 
undervaccinated before age 2 years for Hepatitis B 
(Hep B), rotavirus, DTaP, Haemophilus influenzae 
type b (Hib), pneumococcal conjugate (PC), 
inactivated polio (IPV), measles, mumps, and 
VSD White Paper | Safety of the Childhood Vaccination Schedule 15
rubella (MMR), and varicella vaccines is available 
in Appendix 2.a. These criteria include the 
minimum recommended age for each dose, the 
minimum interval between doses for the same 
vaccine, and the age in days when the count for 
undervaccinated days is initiated for each vaccine 
dose. Over calendar time, some criteria have  
been altered due to policy changes, vaccine 
shortages, and brand-specific dosing instructions  
(Appendix 2.b). 
The days undervaccinated metric has some 
limitations because it does not account for the 
fact that children can be undervaccinated for 
more than one vaccine on a given calendar day. 
For example, if a child is undervaccinated for 
DTaP and Hib vaccines on the same calendar 
days, they would be assigned the same number 
of days undervaccinated as a child who was 
undervaccinated only for DTaP on those same 
days. If accounting for undervaccination across 
multiple vaccines is of interest, we suggest two 
metrics described in the next two sections: 
average days undervaccinated and proportion of 
days undervaccinated.
Figure 2.a: Example of calculating days undervaccinated for DTaP vaccine4 
Average days undervaccinated
ADU is a summary measure of undervaccination 
that expands upon the metric developed by Luman 
et al.3,4 by incorporating days undervaccinated 
across multiple overlapping vaccines. To 
calculate ADU, the days undervaccinated for 
each dose are summed across all vaccine doses 
to calculate cumulative days undervaccinated for 
each child. Then, for each child, the cumulative 
days undervaccinated is divided by the number 
of vaccines that a child should have received 
according to the ACIP schedule. This calculation 
represents the average number of days 
undervaccinated across all recommended vaccines.
An example of calculating ADU is provided in 
Figure 2.b. In this example, days undervaccinated 
before age 2 years have been calculated for 
eight recommended childhood vaccines. These 
days are summed to calculate the cumulative 
days undervaccinated. The cumulative days 
undervaccinated are then divided by 8 to 
calculate the average days undervaccinated. VSD 
analysts have developed a suite of SAS® macros 
(SAS Institute, Cary, North Carolina) to facilitate 
calculation of days undervaccinated and ADU.
Age (in days) considered late for each DTaP vaccine dose per ACIP Schedule
Total days undervaccinated for DTaP for this child = 44 + 46 + 122 + 79 = 291 days
Days 
undervaccinated 
per dose
DTaP1
DTaP1
93 days
137 days
44 days 46 days 122 days 79 days
154 days
200 days
215 days
337 days
580 days
659 days
DTaP2
DTaP2
DTaP3
DTaP3
DTaP4
DTaP4
 Example: Age (in days) for 4 DTaP doses for a hypothetical child receiving all doses late
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Figure 2.b: Example of calculating average days undervaccinated (ADU) across eight recommended childhood 
vaccines before age 24 months3 
Proportion of days undervaccinated 
Proportion of days undervaccinated is a metric 
developed by Opel et al.,31,32 and is similar to 
ADU. The first step is to quantify the total possible 
days undervaccinated over a period of time for 
each recommended vaccine. The sum of these 
days represents the denominator. The numerator 
is the sum of the actual number of days the child 
was undervaccinated for each vaccine. Table 2.c 
shows the proportion of days undervaccinated 
metric applied to the same example as Figure 2.b. 
Table 2.c: Example of calculating proportion of days undervaccinated across eight recommended childhood 
vaccines before age 730 days3,31,32 
Vaccine Maximum number of possible days 
undervaccinated at age 730 days*
Actual number of days undervaccinated 
using example from Figure 2.b
Proportion of days  
undervaccinated
Hepatitis B 730 – 92 = 638 0
DTaP 730 – 92 = 638 62
Rotavirus** 252 – 92 = 160 0
Hib 730 – 92 = 638 62
PC 730 – 92 = 638 0
IPV 730 – 92 = 638 62
MMR 730 – 488 = 242 242
Varicella 730 – 488 = 242 242
Total 3834 (denominator) 670 (numerator) 17.48%
* The latest age a child can receive the first dose of Hepatitis B, DTaP, Rotavirus, Hib, PCV and IPV vaccines on-time per the ACIP schedule is 92 days. The latest age a 
child can receive the first dose of MMR and varicella vaccines on-time is 488 days.23
** Per ACIP recommendations, rotavirus vaccine should not be administered past age 252 days.23
Days delayed 
 for Rotavirus vaccine: 
0 days
Days delayed  
for Hib vaccine: 
62 days
Days delayed  
for PC vaccine: 
0 days
Days delayed  
for DTaP vaccine: 
62 days
Days delayed  
for varicella vaccine: 
242 days
Days delayed  
for MMR vaccine: 
242 days
Days delayed  
for Polio vaccine: 
62 days
Days delayed for Hep B 
vaccine: 
0 days
Cumulative days undervaccinated  
= 0 + 62 + 0 + 62 + 0 + 62 + 242 +242  
= 608 days
Average days undervaccinated  
= 608 / 8 vaccines  
= 76 days
VSD White Paper | Safety of the Childhood Vaccination Schedule 17
Combined Series Completion
Another method that can be used for identifying 
undervaccinated children is combined series 
completion metrics. Combined series completion 
is a cross-sectional measure of whether a child 
is up-to-date for recommended vaccinations. 
Using this method, a child’s vaccination status 
is examined at a point in time, and the doses 
received for recommended vaccines up until 
that point are compared to the number of doses 
the child should have received. CDC’s National 
Immunization Survey uses several combined series 
completion metrics (Table 2.d) to assess whether 
a child is age-appropriately vaccinated at age 
19-35 months.9 As compared to ADU, combined 
series completion only assesses undervaccination 
at the point of measurement and does not capture 
previous periods of undervaccination. In addition, 
while the NIS does report rotavirus series 
completion separately, this series is not currently 
incorporated in its combined series metrics.
Table 2.d: Combined series completion metrics used by the National Immunization Survey for children ages  
19-35 months9 
Metric
≥ 4 doses 
DTaP
≥ 3 doses 
Polio
≥ 1 dose 
MMR
≥ 3 doses 
Hib
≥ 3 doses 
Hep B
≥ 1 dose 
Varicella
≥ 4 doses 
PCV
4:3:1:3:3:1:4 X X X X X X X
4:3:1:3*:3:1:4 X X X 3 or 4 doses* X X X
4:3:1:3*:3:1 X X X 3 or 4 doses* X X Excluded
4:3:1:-:3:1:4 X X X Excluded X X X
4:3:1:-:3:1 X X X Excluded X X Excluded
X=included in metric
* Depending on brand of Hib vaccine
Additional data sources: State immunization registries
When children appear undervaccinated in VSD 
databases, it is possible that these children have 
received vaccines outside of their MCO site. 
Immunization information systems (IIS) are 
confidential, population-based, computerized 
databases that record all vaccination doses 
administered by participating providers to people 
residing within a given geographic area.33 IIS 
are used in clinical settings to gain access to 
consolidated immunization histories to assist 
vaccination providers in determining appropriate 
patient vaccinations. At the population level, 
an IIS provides aggregate data on vaccinations 
for use in assessments of coverage, program 
operations, and in guiding public health action 
to improve vaccination rates.34 There are many 
initiatives underway to support interoperability 
of systems which are expected to result in more 
complete and timely immunization histories in 
IIS, including the Health Information Technology 
for Clinical and Economic Health (HITECH) Act35 
as well as aspects of the Prevention and Public 
Health Fund (PPHF), and the Centers for Medicare 
and Medicaid Services meaningful use projects.36
For healthcare systems, adoption of IIS as the 
vaccination database, or incorporation of IIS data 
into existing EHR records through automated data 
exchange, can improve the capacity to estimate 
vaccination coverage levels among patients. 
Health care systems that employ bidirectional data 
exchange with an IIS are well equipped to examine 
the prevalence of childhood undervaccination 
as they are able to access more complete 
immunization histories. Many VSD sites already 
link IIS records into their VSD vaccine files, and 
misclassification of missing vaccination data may 
be reduced at these MCOs.37 
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Stage 2: Characterize patterns of undervaccination 
After a cohort of undervaccinated children has 
been identified, children can be further grouped 
by patterns of undervaccination using one or 
more of the suggested methods described below 
(Table 2.e). These groups of undervaccinated 
children can be included in safety studies, 
provided they are large enough to study the 
outcome of interest and there is minimal potential 
for bias from misclassification and confounding. 
If small sample sizes, misclassification or 
confounding are a concern, the groupings of 
children can be further refined analytically in 
stage 3 and then verified in stage 4 using primary 
data collection. 
Table 2.e: Approaches for characterizing patterns of undervaccination using VSD data3,28,30,38 
• Completely undervaccinated (zero vaccines)
• Published alternative schedules (ex: The Vaccine Book by Dr. Robert Sears28. 
• Limiting the number of vaccines given per visit (“shot-limiting”)30
• Delaying start to vaccination 
• Vaccine series not received
• Vaccine doses not received
• Age of receipt of each vaccine dose
• Spacing of vaccines
• Order of vaccines
• Cumulative exposure to vaccine antigens
• Cumulative exposure to other vaccines ingredients (ex: aluminum)
Completely unvaccinated (zero vaccines)
In the VSD, identifying children with no 
vaccination records is straightforward. A previous 
VSD study estimated that approximately 1% 
of children had no vaccine records before age 
24 months3. However, children who appear 
completely unvaccinated in VSD data are likely 
a mix of the truly unvaccinated and children 
whose vaccination status is misclassified. The 
misclassification can be due to children receiving 
vaccines outside of the MCO or missing electronic 
vaccine records. Additional utilization and health 
plan criteria could be applied to increase the 
likelihood that completely unvaccinated children 
were receiving regular care within the managed 
care organization (MCO). 
Published alternative schedules
VSD data can be used to identify vaccination 
patterns associated with known alternative 
vaccination schedules, such as those created by 
Drs. Robert Sears, Elizabeth Mumper, Donald 
Miller, Stephanie Cave, and Kenneth Bock.28,39-42 
Features of these alternative schedules include 
spacing vaccinations over multiple visits, delaying 
the start of any vaccinations until a later age, 
and forgoing certain vaccine series altogether. 
While vaccination patterns consistent with these 
alternative schedules have been identified within 
the VSD pediatric cohort, the percentage of 
vaccine-hesitant parents strictly adhering to one 
of these schedules is small.3,14 For example, in 
a previous VSD study, only 0.68% of children 
appeared to be receiving vaccinations according 
to the Alternative or Selective Schedules 
recommended by Dr. Robert Sears in The Vaccine 
Book.3,28 
Limiting the number of vaccinations per 
visit (“shot-limiting”)
Shot-limiting refers to a parental behavior of 
requesting fewer than the recommended number 
of vaccine doses at a given immunization visit.30 
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While the term “shot-limiting” implies injections, 
the total number of vaccines (injected or oral) per 
visit can also be examined. Factors influencing 
how many vaccines a child should receive are the 
MCO’s formulary and the child’s age. Per current 
ACIP guidelines, children should receive between 
three and six vaccines at 2- and 4-month well-
child visits. 
To examine the behavior of limiting the number 
of vaccinations per visit in VSD data, children can 
be categorized by the proportion of visits where 
shot limiting behavior was observed (consistent or 
episodic). Children can also be categorized by the 
extent of shot limiting; for example, the average 
number of vaccine doses per visit over a period of 
time. Shot limiting could also be assessed by the 
average number of antigens per visit or average 
ingredient exposure (ex: milligrams of aluminum) 
per visit. A study using Oregon state immunization 
registry data found that 4.6% of their study 
population received 2 or fewer immunizations 
at all visits before age 9 months, suggesting 
that these parents were consistently limiting the 
number of shots given to their children.30 Data 
from a current VSD study indicate that 1.36% of 
children appear to receive 2 or fewer vaccines at 
all immunization visits before age 12 months.43 
Delaying start to vaccination
In VSD data, children with a delayed start to 
vaccination have no immunization records until a 
certain age, after which they may have received 
some or all recommended vaccines. In prior VSD 
work, children who received their first vaccines 
at ages 4-5, 6-11, 12-23 and 24 months were 
identifi ed.3 Approximately 1.29% of children 
received their first vaccination at age 4 months or 
later. Children with a delayed start to vaccinations 
can catch up and be considered up-to-date at a 
later age. When evaluating ADU or up-to-date 
status, the ACIP catch-up schedule should be 
considered.23 
Vaccine series not received
Immunization patterns can be classified by vaccine 
types not received. Such classification is especially 
helpful in describing parental refusal of entire 
vaccine series. When using this metric, potential 
misclassification of vaccination data should be 
evaluated (i.e., children may be receiving vaccines 
outside the MCO). Additional utilization and 
health plan criteria could also be implemented 
to increase the likelihood that a child is getting 
regular care within the MCO. Also, as the number 
of recommended childhood vaccines considered 
increases, so does the dimensionality of this 
metric. For example, if considering whether or 
not a child started each of eight recommended 
vaccine series (yes/no) before age 2, there are 28 
= 256 possible patterns. In a recent VSD analysis, 
156 such patterns were observed before age 2 
among a cohort of about 240,000 children.43 
Vaccine doses not received
Alternative vaccination schedules can be further 
classified by the number of recommended doses 
of a vaccine not received. This metric can be 
applied to each specific vaccine or more broadly 
across all vaccines. The denominator of how many 
doses a child should have received should be 
considered and is influenced by several factors: 
(1) calendar time, as new vaccines are added to 
the ACIP schedule, (2) age, since the number 
of recommended doses vary by age, and (3) 
vaccine brand, since the number of recommended 
doses for some vaccines differs by brand. This 
metric can be easily quantified using VSD data. 
However, potential misclassification of missing 
doses merits additional evaluation, and the high 
dimensionality of this metric may cause challenges 
in identifying large groups with similar patterns 
of undervaccination. For example, in a recent VSD 
analysis, the number of doses not received was 
assessed for each of eight recommended vaccines 
before age 2. Within a cohort of about 240,000 
children, 2376 distinct patterns of doses not 
received across the eight vaccines was observed.43
Age of receipt of each vaccine dose
Children’s vaccination patterns can be described 
by the age of receipt of each vaccine dose. In the 
general population the distribution of age at each 
dose will be centered on the ACIP-recommended 
age. Among undervaccinated children, these age 
distributions will be more variable. Days, weeks 
or months are appropriate units of age when 
describing age of receipt of vaccine doses for 
young children. 
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Spacing of vaccines
The spacing of vaccine doses can refer to the 
amount of time that elapsed between doses of 
the same vaccine series, or to the amount of time 
between administrations of different vaccine 
series. When evaluating a cumulative vaccination 
schedule, examining the spacing of doses as 
a metric can be complex given the number of 
vaccine series and doses that can be spread across 
the first few years of life. 
Order of vaccines
For undervaccinated children, the order in which 
vaccines are given can differ from the order 
specified on the ACIP schedule. When describing 
a vaccination schedule using this method, 
researchers are typically interested in the order 
vaccine doses were administered over multiple 
immunization visits, not on a single visit.44 As with 
other metrics relating to the timing of vaccines, 
evaluating a cumulative vaccination schedule 
based on vaccine order can be cumbersome given 
the numerous possibilities for how all of the 
recommended vaccines can be ordered. 
Exposure to vaccine antigens
Exposure to vaccine antigens can be estimated using 
VSD data. When describing a child’s vaccination 
pattern, exposure to antigens can be measured at 
various points in time (e.g., at each immunization 
visit) or summed as a cumulative measure over 
time. Cumulative antigen exposure has previously 
been studied with VSD data. For example, Iqbal et 
al., used a combination of MCO vaccination records 
and parent-reported data to examine the association 
between cumulative exposure to antigens and 
neuropsychological outcomes.38 
Exposure to other vaccine ingredients
Along with antigens, vaccines contain other 
components used in the manufacturing process. 
Such non-antigen vaccine ingredients include small 
amounts of preservatives, adjuvants, additives, 
and residual substances.45,46 Metrics summarizing 
exposure to some of these ingredients is possible 
with VSD data. Preliminary data from a recent 
VSD study demonstrated that it is feasible to 
quantify vaccine aluminum exposure in a study 
population of more than 400,000 children 
from birth to 24 months of age. Considerable 
variability in aluminum exposure was observed 
in this large cohort, suggesting the potential to 
compare outcomes in children with varying levels 
of exposure to aluminum from vaccinations. The 
key to this analysis was the completeness of 
manufacturer data in the VSD vaccination data 
file, which could be linked to the vaccine package 
inserts to quantify the ingredient amounts in each 
vaccine dose. Manufacturer data was approximately 
70% complete between years 2004 and 2013.43 
Stage 3: Use additional VSD data 
to address sample size, exposure 
misclassification & potential confounding
As shown in stage 2, there are numerous 
approaches for characterizing patterns of 
undervaccination in the VSD. For stage 3, we 
describe three methods for addressing potential 
issues with small sample sizes, misclassification 
and confounding. For small sample size concerns, 
we describe a data mining analytic approach for 
creating groupings of undervaccinated children. 
To address misclassification of vaccination data, 
we discuss a method using the ICD-9 code for 
vaccine refusal. Lastly, we describe how VSD 
utilization data can be used to help address 
confounding and misclassification of vaccination 
and outcome data. 
Application of data-mining techniques
Pattern discovery techniques, such as cluster 
analysis (or data segmentation)47 may be used to 
help identify distinct groups of undervaccinated 
children with closely-related immunization 
patterns. After a large dataset of undervaccinated 
children has been identified, cluster analysis can 
be implemented in three steps. First, children’s 
vaccination patterns are defined using the 
approaches outlined in Stage 2. Second, a measure 
of proximity (also referred to as a distance 
measure) is used to quantify how similar every 
child’s pattern of vaccination is to every other 
child in the dataset. Third, a clustering technique 
is applied to identify groups with similar 
vaccination patterns. 
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For this last step, two general methods can be 
considered: k-means clustering and agglomerative 
hierarchical clustering.47,48 For k-means methods, a 
k number of cluster “centers” are pre-defined by the 
user.48,49 For example, these centers could reflect 
published alternative schedules, and children 
would be assigned to their closest center based 
on established algorithm. With agglomerative 
hierarchical clustering, pre-defined cluster centers 
are not required. Each child is considered its own 
cluster, and children are linked together to form 
larger and larger clusters until all children are in 
one cluster (consisting of the entire dataset). Once 
this hierarchical representation is established, data 
are examined at various cut-points to determine the 
appropriate number of clusters.47,48 
Along with cluster analysis, other techniques 
such as principal component, latent variable, and 
factor analysis may be considered. In general, 
these other methods can aid in reducing the 
dimensionality of a dataset, or in identifying latent 
groups or constructs to help identify groupings of 
undervaccination. 
One notable limitation of clustering methodologies 
are their computational time and space. Some 
clustering methods will involve creating an N x 
N matrix; since pediatric VSD cohorts often have 
hundreds of thousands of children, creating such 
a relational dataset may be a challenge. Statistical 
packages such as R (R Foundation for Statistical 
Computing, Vienna, Austria) and SAS Enterprise 
Data Miner® (R Foundation for Statistical 
Computing, Vienna, Austria) should be considered 
for conducting these large-scale analyses.
ICD-9-CM code for parental refusal of 
vaccination
As described, previous VSD work has shown that 
there is minimal misclassification of vaccination 
exposure status among children with a diagnosis 
for parental refusal or delay of vaccination (V64.05 
and V64.06) in their electronic health record data.3 
As such, if cohorts of undervaccinated children are 
restricted to only those with these ICD-9 codes, 
then misclassification of vaccination status is likely 
low and no additional primary data collection may 
be needed. However, a major limitation is that only 
a small percentage (≈ 12%) of undervaccinated 
children has this diagnosis code recorded in their 
electronic health record, and prevalence of this 
code varies by VSD site.49 Since the recording 
of this ICD-9 code in a child’s electronic health 
record is a provider-level behavior, it should not be 
assumed that children with this code recorded are 
representative of all undervaccinated children.
Utilization data
The potential for information bias among MCO 
members with low levels of health care utilization 
has been previously noted within the VSD.3,50 
For example, one VSD study initially observed 
a positive association between Hib and Hep B 
vaccination and the incidence of asthma, but the 
association was no longer evident once the study’s 
cohort was restricted to children with at least two 
outpatient visits. The authors hypothesized that 
children with fewer than two outpatient visits 
were more likely to be receiving care outside of 
the MCO and to have misclassified vaccination and 
outcome data.50 In addition to misclassification, 
differences in health care utilization between 
vaccination and undervaccinated children may 
lead to confounding if the utilization is associated 
with both the likelihood of receiving vaccines and 
being diagnosed with an adverse event. 
To avoid this potential for bias, researchers may 
consider restricting their study populations to 
children with a minimum amount of health care 
utilization. There are two main challenges with this 
approach. One, the baseline level of utilization that 
is needed to minimize bias is currently not known. 
This could be potentially assessed through primary 
data collection such as medical record review or 
surveys (see stage 4). Two, VSD does not have an 
encounter-level data file, so utilization must be 
assessed by proxy from diagnoses and procedures 
data. In addition, certain types of utilization—
such as phone and email encounters—are also 
excluded from the VSD data files. The VSD may 
want to consider including all procedure code 
data, and collect additional information from EHR 
encounters, including encounter subtypes and 
department codes. 
Stage 4: Validate with primary data 
collection (manual medical record 
reviews/surveys)
After groups of undervaccination have been 
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identified, health care utilization behaviors and the 
potential for missing immunization data can be 
further evaluated through primary data collection. 
For stage 4, we describe two methods of data 
collection: manual medical record review and 
surveys with parents. These methods can either 
be applied in one large comprehensive VSD study, 
or VSD investigators can apply the methods on 
a smaller scale to address issues specific to their 
individual studies.
Medical record review 
A manual medical record review could be used to 
confirm vaccination status, to determine if reasons 
of undervaccination are due to parental refusal or 
delay, and to assess whether the child is receiving 
care outside of the MCO. The review could be 
conducted across strata of undervaccination and/or 
strata of health care utilization. A formal abstraction 
tool should be developed, and Table 2.f shows 
examples of data elements that could be collected 
with the tool. Many of these data elements were 
captured with a tool developed for the recently 
published study on undervaccination in the VSD.3 
The data collected from the tool can be used to 
calculate confirmation rates, representing the 
following: the proportion of children who were 
undervaccinated due to intentional refusal or 
delay, the proportion with missing immunization 
data, and the proportion who were receiving their 
primary care outside of the MCO. Confirmation 
rates can be calculated for each specific pattern of 
undervaccination to help identify exposure groups 
in which misclassification of vaccination status is 
minimized.
Table 2.f: Example of data elements to be collected within a chart abstraction tool
Item Notes
VSD ID
Date of 1st vaccination
Any documentation that the parent intentionally refused recommended 
vaccines?
Any documentation that the parent intentionally delayed receiving 
recommended vaccines?
Any documentation that the provider specifically recommended delaying 
vaccines due to current illness?
Any documentation that the provider specifically recommended delaying 
vaccines for a non-medical reason?
Any documentation that the parent specifically requested delaying vaccines 
due to current illness?
Any documentation that the child had a medical contraindication to 
vaccination?
Contraindications would include immunosuppression (for certain vaccines), 
anaphylactoid reaction to a prior vaccine dose, severe egg allergy (for certain vaccines)
Any documentation that the child was in fact up-to-date on vaccines? For example, because of vaccines documented in record or received at outside 
location
Any documentation that the child/family faced barriers to vaccination other 
than parental vaccine refusal/delay?
Examples of barriers include lack of transportation to appointments, having to take 
time off from work to bring to appointment, having unintentionally missed well-
child visits, having temporarily moved out of state
Any other documentation regarding why the child was undervaccinated?
Any indication within records that the child has ever obtained health care 
from an alternative medicine provider (such as a chiropractor, naturalist, 
homeopath, or acupuncturist)?
Any evidence that the child is receiving primary care outside of the MCO?
VSD White Paper | Safety of the Childhood Vaccination Schedule 23
Survey of parents 
It is possible that a medical record review will 
yield inconclusive results, since prior work has 
demonstrated that reasons for undervaccination 
are frequently absent from the medical records. 
A survey of parents may therefore be used to 
provide more accurate data on the following: 1) 
whether children who appear undervaccinated are 
truly undervaccinated or have received vaccines 
elsewhere; 2) whether undervaccination is due to 
parental vaccine refusal/delay or other reasons; 
and 3) whether undervaccinated children have 
received health care outside of the system. In 
addition, the survey could assess information that 
is typically not available from the medical record, 
including child and family characteristics, health 
care seeking behaviors, the general health status 
of undervaccinated children, and vaccination 
guidance given by providers and medical staff.
A two-step approach can be used to develop the 
survey instrument. The first step is to develop the 
survey questions and a preliminary survey; the 
second step is to pilot test the survey. 
Develop survey questions
To develop the survey questions, the research 
team could first identify relevant questions based 
upon previously administered surveys, such as the 
National Immunization Survey51,52 and the National 
Survey of Children’s Health.53 After identifying 
previously published questions, the team can 
develop questions that are tailored to the children’s 
particular vaccination patterns. In key content 
areas, researchers can include several questions 
with similar content but different wording, which 
will facilitate survey revision after pilot-testing. A 
table of the main content domains and example 
survey questions are shown in Appendix 2.c. 
Pilot test preliminary survey
After a preliminary survey has been developed, 
it can be pilot tested using a variety of methods. 
Cognitive interviews can be conducted with a 
small sample of 5-10 parents to elicit feedback 
on each question, focusing on wording, tone and 
comprehension. The results from these discussions 
can be used to further refine the survey, by adding, 
eliminating or changing the wording of questions. 
In addition to cognitive interviews, the survey 
can be administered to a larger sample of parents 
and analyzed using an exploratory factor analysis. 
A factor analysis on the survey questions will 
identify the number of constructs (factors), 
determine which survey questions load on to 
the constructs, and determine which survey 
questions can be excluded from the final survey 
instrument.54,55 After the factor analysis, the 
reliability (or internal consistency) of the latent 
constructs can be measured with a Cronbach’s 
alpha.56 This analysis can be used as a guide to 
eliminate survey questions that do not contribute 
to the constructs. 
At the conclusion of the pilot testing, investigators 
will have a final version of the survey that can be 
administered to formally assess vaccination status, 
vaccination behaviors and health care seeking 
behaviors among parents of undervaccinated 
children. 
Survey administration 
Researchers should strive for a 50% or greater 
response rate on their surveys. This can likely be 
achieved using one or more acceptable methods 
of survey administration, including telephone, 
conventional mail, or email. The timing and 
sequence of these methods can be based on the 
Dillman protocol for survey administration.57 Since 
resources may be limited, both conventional mail 
and email should be strongly considered, as VSD 
sites generally have accurate mailing addresses on 
their patient populations and email addresses are 
available for approximately 80% of the members at 
many of the VSD MCO sites. 
Sampling scheme for medical record review 
and parent survey
The following factors should be considered when 
determining the appropriate sample size for a 
medical record review or survey:
• Whether the sample is stratified (e.g., 
undervaccination, health care utilization,  
VSD site)
• Range of estimated confirmation rates 
• Desired confidence interval width
• Available resources
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Appendix 2.d shows estimated sample sizes across 
a range of confirmation rates and confidence 
interval widths for a hypothetical medical record 
review and/or survey study. 
Analysis of medical record and survey data
The data collected from a medical record 
review and survey will help provide estimates 
of misclassification of exposure and health care 
utilization, which in turn will inform how to 
define exposure groups for future safety studies. 
In the analytic methods section (chapter 4), 
we describe sensitivity analyses and simulation 
methods to incorporate the confirmation rates into 
the design and analysis of safety data.
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Chapter 3: Outcomes
3.1 Background
3.2 Generate list of potential outcomes (Phase 1)
3.3 Subject Matter Expert (SME) engagement (Phase 2)
3.4 Final prioritization (Phase 3)
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3.1 Background
As described in chapter 1, the IOM’s 2013 report1 
recommended additional observational studies 
to better understand the safety of the entire 
childhood immunization schedule. In addition 
to identifying meaningful exposure groups of 
undervaccination and alternative immunization 
schedules, the report stressed the importance of 
assessing plausible adverse event outcomes that 
could be studied in relation to the childhood 
immunization schedule as a whole. In particular, 
the IOM suggested three criteria for identifying 
possible outcomes: epidemiological evidence, 
biologic plausibility, and stakeholder concern.
Identifying outcomes for observational studies in 
the VSD are typically conducted in four steps. In 
step 1, potential adverse events are identified in 
the automated medical encounter databases using 
ICD-9-CM codes. In step 2, trained abstractors 
– blinded to vaccination status – conduct a 
medical record review on the potential events to 
record the onset and timing of the events. The 
medical record review also documents additional 
clinical information that is not captured in the 
automated databases, such as symptoms, sequelae, 
medications administered, alternate diagnoses, 
referrals to specialists, and laboratory test results. 
In step 3, clinician investigators adjudicate the 
potential cases by validating the onset and timing 
of the event, and whether or not the event could 
be attributed to a cause other than vaccination. 
The results from the medical record review are 
used to calculate a confirmation rate, measuring 
the proportion of validated cases identified by 
ICD-9-CM codes. Past VSD studies show that 
confirmation rates for outcomes can range from 
10% to 90%.26,59-61 Lastly, in step 4, the validated 
cases are linked to their immunization records and 
prepared for analysis. With a case-control study, 
the cases are typically matched to non-disease 
controls by age, sex and MCO; for a cohort study, 
the cases are merged with a large population 
of vaccinated and unvaccinated individuals. All 
of these methods are then used to determine if 
vaccination is associated with a hypothesized 
adverse event. 
In this chapter, we describe a rigorous multi-
phased approach by which we identified, 
categorized and prioritized outcomes that the VSD 
could evaluate in the context of the childhood 
immunization schedule. This process was 
conducted in the following 3 phases (Figure 3.a): 
1. Generate list of potential outcomes
2. Subject matter expert (SME) engagement 
3. Final prioritization
Throughout the process we considered several 
criteria, including biologic plausibility, feasibility 
to study in the context of the entire immunization 
schedule, existing epidemiological evidence, 
feasibility to study in the VSD, public health 
significance, and public concern. 
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Figure 3.a: Process overview for identifying and evaluating outcomes 
3.2 Generate list of potential outcomes (Phase 1)
The objective of the first phase was to compile a 
large, inclusive list of potential adverse outcomes 
that could be associated with the complete 
childhood immunization schedule. The initial 
sources of information were IOM reports from 
2002, 2011 and 2013.1,58,62 In addition to the IOM 
reports, Pubmed searches were conducted with 
the following search terms to broadly address 
vaccine-associated adverse events: “vaccine OR 
vaccination OR immunization” AND “adverse 
event OR adverse OR post-immunization OR 
post-vaccination”. There were no time restrictions 
applied to the publication dates of the search. 
References generated from the search were 
directly downloaded into EndNote (version X4, 
Thomson Reuters), and reviewed by the study 
team to identify articles related specifically to 
vaccine adverse events (e.g., vaccine efficacy or 
effectiveness studies were removed). This yielded 
epidemiological studies that either supported or 
rejected causal associations, as well as case reports 
suggesting potential linkages between vaccines and 
suspected adverse events. These outcomes were 
then grouped with the outcomes from the IOM 
reports, resulting in an initial list of 75 outcomes 
(Table 3.a) organized by either organ type (e.g., 
respiratory system, neurologic system) or reaction 
type (e.g., allergy, anaphylaxis). 
For each outcome, the study team summarized 
and reviewed available evidence related to 
biological and mechanistic plausibility, and 
appropriateness of evaluating the adverse event 
in the context of the childhood immunization 
schedule. To determine biological plausibility, 
the study team assessed existing evidence of 
potential associations between specific aspects 
of the immunization schedule and particular 
adverse health outcomes. Moreover, the team 
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 outcomes grouped 
n= 31 outcomes
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Generate list of potential outcomes
Ranked outcomes according to  
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 public concern
n= 20 outcomes
Subject matter expert review and 
prioritization
n= 47 outcomes
Identified outcomes that were plausibly 
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evaluated potential mechanisms by which receipt 
of all childhood immunizations could impact 
biological functions leading to the development 
of an adverse event. To assess appropriateness 
of evaluating an outcome relative to the entire 
schedule, the study team considered the acute/
chronic nature of the outcome and the age at 
peak incidence. In addition, the team reviewed the 
existing epidemiological evidence to determine 
if outcomes could be clearly linked to a specific 
vaccine or combination of vaccines, suggesting 
that such outcomes should not be studied in 
relation to the entire schedule. 
After internal discussions among the study team 
using these criteria, 28 outcomes were removed 
from the list. For example, outcomes such as 
stroke and myocardial infarction were not 
considered plausible for evaluation relative to the 
childhood immunization schedule given the later 
age of peak incidence and relatively low incidence 
among children. Additionally, outcomes such 
as serum sickness/Arthus reaction and measles 
inclusion body encephalitis were not considered 
plausible because of the direct association with 
specific vaccines and lack of biological plausibility 
for an association with the immunization 
schedule as a whole. Similarly, thrombocytopenia 
and immune thrombocytopenic purpura were 
excluded since they are known acute adverse 
events of specific vaccines. 
At the conclusion of phase 1, the list of 75 
outcomes was reduced to 47 plausible outcomes 
that could be studied relative to the childhood 
immunization schedule as a whole (Table 3.a).
Table 3.a: List of 75 outcomes identified for evaluation; 47 bolded outcomes were initially considered plausible 
to study relative to the childhood immunization schedule
All Cause
1. All cause morbidity
2. All cause mortality
Allergy/allergic condition
3. Allergy development
4. Asthma development
5. Anaphylaxis
6. Chronic urticaria
7. Asthma exacerbation
Autoimmune disease
8. Crohn’s disease and ulcerative colitis
9. Kawasaki’s disease
10. Type 1 Diabetes
11. Autoimmune hepatitis
12. Psoriatric arthritis
13. Juvenile rheumatoid arthritis
14. Systemic lupus erythematosus
15. Multiple sclerosis
16. Autoimmune thyroiditis (Hashimoto’s)
17. Autoimmune thyroiditis (Grave’s)
18. Rheumatoid arthritis
Blood/circulatory system disorders
19. Hypercoaguable states
20. Immune thrombocytopenia purpura
21. Polyarteritis nodosa
22. Thrombocytopenia
23. Thromboembolic events
Bone/joint
24. Ankylosing spondylitis
25. Arthropathy / chronic arthropathy
26. Arthalgia (chronic and transient)
27. Juvenile idiopathic arthritis
28. Polymyalgia rheumatica
29. Reactive arthritis
Demyelinating neurologic disorders
30. Acute disseminated encephalomyelitis
31. Chronic inflammatory demyelinating 
polyneuropathy
32. First demyelinating event
33. Guillain-Barre syndrome
34. Neuromyelitis optica
35. Optic neuritis
36. Transverse myelitis
Cardio/cerebro-vascular system
37. Myocardial infarction
38. Myocarditis and pericarditis
39. Stroke
Seizures
40. Epilepsy
41. Infantile spasms
42. Afebrile seizures
43. Febrile seizures 
44. Other seizures
Other:
45. Erythema nodusum
46. Fibromyalgia
47. Oculorespiratory syndrome
48. Pancreatitis
49. Serum sickness and arthus reaction
50. Sudden infant death syndrome
51. Uveitis
Neurologic system
52. Autism spectrum disorders
53. Bell’s Palsy
54. Brachial neuritis
55. Cerebellar ataxia/ ataxia
56. Encephalitis
57. Encephalopathy
58. Meningitis
59. Narcolepsy and cataplexy
60. Syncope and vasovagal reaction
61. Learning, communication, and 
developmental disorders
62. Attention deficit disorder
63. Tourette’s syndrome
64. Tics
65. Chronic fatigue syndrome
66. Amyotrophic lateral sclerosis
67. Chronic headache
68. Hearing loss
69. Opsoclonus myoclonus syndrome
70. Small fiber neuropathy
Varicella-zoster virus related conditions
71. Disseminated Oka varicella zoster virus, with 
subsequent infection
72. Disseminated Oka varicella zoster virus without 
organ involvement
73. Varicella zoster virus reactivation with 
subsequent infection
74. Varicella zoster virus reactivation without 
organ involvement 
Measles virus related conditions
75. Measles inclusion body encephalitis
VSD White Paper | Safety of the Childhood Vaccination Schedule 29
3.3  Subject Matter Expert (SME) 
engagement (Phase 2)
Once the initial list of 47 outcomes was in place, 
Emory University hosted a day-long meeting on 
February 25th, 2014, with VSD staff and three 
outside, internationally regarded experts in the 
area of vaccine science. The subject matter experts 
were Dr. Walter Orenstein of Emory University, Dr. 
Stanley Plotkin of the University of Pennsylvania, 
and Dr. Edgar Marcuse of the University of 
Washington. The objective of the meeting was to 
gain additional insight into the appropriateness of 
studying specific outcomes in the context of the 
childhood immunization schedule and to conduct 
an initial prioritization of the outcomes. 
For the first two hours of the meeting, the study 
team and SMEs had an open discussion about 
each of the 47 outcomes, focusing on biologic 
plausibility, relevance to the entire immunization 
schedule, and feasibility to study in the VSD. After 
the discussion, the SMEs were instructed to classify 
each outcome as “include” or “exclude”. The SMEs 
were also asked to comment on whether additional 
information (or data) was needed to determine the 
feasibility of studying the outcome relative to the 
entire immunization schedule within the VSD.
Of the 47 outcomes, the SMEs concluded that 
the following 4 outcomes could be excluded: 
Hashimoto’s thyroiditis, Grave’s disease, opsoclonus 
myoclonus syndrome and small fiber neuropathy. 
The first two were excluded because they rarely 
occur during childhood; the latter two were 
eliminated because they are extremely rare in the 
general population.
For the remaining 43 outcomes, the SMEs made 
several suggestions. First, since the emphasis 
was on long-term outcomes, the SMEs were 
concerned that outcomes with insidious onsets, 
long latencies, or unclear diagnostic characteristics 
(e.g., narcolepsy, fibromyalgia) would be difficult 
to study. They therefore stressed the importance of 
focusing on outcomes with clear diagnostic criteria, 
such as those having a definitive clinical diagnostic 
test or by having the ability to confirm case status 
with a manual medical record review. Second, 
the SMEs expressed the need to strongly consider 
public concern when deciding on outcomes to 
study. They said that, in certain instances, public 
concern may be a more important consideration 
than biologic plausibility. Some of the outcomes 
on the list – such as all cause morbidity/mortality 
and attention deficit disorder – reflect this opinion. 
Finally, the SMEs were concerned that many of the 
outcomes may be too rare to study in the VSD, and 
requested additional age-specific incidence data. 
They further suggested that several of the outcomes 
represented classes of conditions that could be 
grouped together (Table 3.b). For example, the 
SMEs recommended that a single outcome grouping 
called “first demyelinating events” could include 
acute disseminated encephalomyelitis, chronic 
inflammatory demyelinating polyneuropathy, 
Guillain-Barre syndrome, neuromyelitis optica, optic 
neuritis, and transverse myelitis. 
Table 3.b: Individual outcomes that were grouped
Outcome group  Individual Outcomes
First demyelinating 
event
• Acute disseminated encephalomyelitis
• Chronic inflammatory demyelinating polyneuropathy
• Guillain-Barre syndrome
• Neuromyelitis optica
• Optic neuritis
• Transverse myelitis
Seizures • Febrile seizure
• Afebrile seizure
• Other seizures (seizures not otherwise specified)
Tics • Tics
• Tourette’s syndrome
Despite the emphasis on long-term outcomes, 
there was also considerable discussion on the 
appropriateness of studying anaphylaxis, which 
is generally considered to be an acute event 
triggered by an acute exposure. However, since 
hypersensitivity reactions need prior sensitization 
to occur, it is possible that repeated exposures 
to a particular antigen or vaccine component 
could lead to the development of an underlying 
hypersensitivity state, which could be triggered by a 
follow-up booster dose. Therefore, it was concluded 
that anaphylaxis represents an acute event that 
may be evaluated in the context of the childhood 
immunization schedule. The final result of the SME 
meeting was an initial list of 31 prioritized outcomes.
3.4 Final prioritization (Phase 3)
Between April and July 2014, the study team 
reviewed the transcripts and formally prioritized 
the list of 31 outcomes using an iterative process. 
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The prioritization incorporated estimates of incident 
diagnoses to determine if outcomes could be 
feasibly studied in the VSD, and a newly developed 
rating system to estimate the public health concern 
and public health significance of each outcome. 
This final phase was conducted in 4 steps. For 
the first step, SAS® programs (SAS Institute, Cary, 
North Carolina) were run against each VSD site’s 
data files to estimate age-specific incidence rates of 
diagnosis for 29 of the 31 outcomes identified in 
phase 2. Incidence rates were not estimated for all-
cause morbidity and all-cause mortality since they 
are not readily estimated from ICD-9-CM codes. For 
the 29 conditions, incidence rates were calculated 
in a cohort of 321,522 children born between 2004 
and 2010. Each child in the cohort had 3 years of 
continuous enrollment from birth (allowing a 6 
week grace period), and children were followed 
for a maximum of 8 years. Outcomes in the cohort 
were represented by electronic ICD-9-CM codes 
determined by the study team (Table 3.c). The first 
occurrence of each outcome during a child’s follow-
up was identified, and crude incidence rates were 
calculated for the 0–2 year and 3–8 year age groups. 
Table 3.c: ICD-9-CM codes used to estimate age-specific incidence rates in VSD data 
Description ICD-CM-9 codes
1 Development of allergy 372.14, 477.x , 495.8x, 495.9x, 558.3x, 558.4, 691.8x, 692.x , 708.x , 995.3x, V15.0x 
2 Asthma 493.x
3 Anaphylaxis 995.0x, 995.1x, 995.2x, 995.3x , 995.4, 995.6x, 999.4x 
4 Chronic urticaria 708.x
5 Crohn’s disease and ulcerative colitis 555.x, 556.x
6 Kawasaki’s disease 446.1x
7 Type 1 Diabetes 250.x
8 Chronic hepatitis 571.4x
9 Psoriatic arthritis 696.0x
10 Juvenile rheumatoid arthritis 714.3x
11 Lupus 710.0
12 Multiple sclerosis 340.x
13 First demyelinating event 323.6x, 341.0x, 341.2x, 357.0x, 357.81, 377.30, 377.31, 377.32, 377.39 
14 Autism spectrum disorders 299.x
15 Bell’s Palsy 351.0x
16 Brachial neuritis 723.4x
17 Cerebellar ataxia 334.3x, 334.4x
18 Encephalitis 049.9x, 323.5x, 323.6x, 323.8x
19 Encephalopathy 348.3x
20 Meningitis 047.9x, 322.x
21 Cataplexy and narcolepsy 347.x
22 Syncope and vasovagal reaction 780.2x
23 Learning, communication, developmental disorders 315.x
24 Attention deficit disorder 314.x
25 Tics and Tourette’s syndrome 307.2x
26 Chronic fatigue syndrome 780.71
27 Epilepsy 345.x but not 345.6x
28 Infantile spasms 345.6x
29 Seizures 780.3x but not 780.33
30 All-cause mortality Incidence rate not assessed
31 All-cause morbidity Incidence rate not assessed
ICD-9-CM=International Classification of Diseases, 9th edition, Clinical Modification
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In step 2, the study team reviewed the incidence 
rates and classified each outcome as being either 
feasible or not feasible to study in the VSD. A 
cut-off incidence of 5 cases per 100,000 years of 
follow-up among children ages 3 to 8 years was 
used, as this is generally the smallest rate by which 
outcomes have been studied in the VSD.61,63,64 This 
step eliminated 10 of the 31 outcomes (Table 3.d).
For step 3, study team members ranked each of 
the remaining 21 feasible outcomes on public 
health significance and public concern. For public 
health significance, team members were asked 
to consider the seriousness of the condition, the 
rarity of the condition, whether the condition 
was increasing in prevalence and whether the 
outcome has already been studied as an adverse 
event. For the last criterion, we assumed that if an 
outcome has been extensively studied as a vaccine 
adverse event, additional studies would not have a 
significant public health impact. For public concern, 
team members considered the seriousness of the 
outcome, and whether vaccine hesitant parents 
would associate the outcome with vaccination. 
Team members based this determination on existing 
vaccine hesitancy research in the literature, our own 
ongoing vaccine hesitancy research, and (where 
applicable) our own clinical experiences. Using 
all of these criteria, team members ranked each 
of the 21 outcomes on a 1 to 5 scale for public 
health significance and public concern. A score 
of 1 represented the lowest ranking and 5 the 
highest. The two scores were then summed together 
and averaged across the study team, resulting 
in a combined score between 1 and 10 for each 
outcome.
In the final step, the rankings were reviewed and 
discussed by the study team. In these discussions, 
team members could make the case to move 
outcomes up, down or off the priority list. For 
example, first demyelinating event was initially 
classified as not being feasible, but was moved up 
the priority list because it is a potentially serious 
outcome that was ranked highly on public concern. 
Autism, in contrast, was moved off the priority list 
because it has been extensively studied relative 
to the vaccination schedule,38,65-67 despite its high 
public concern ranking. The final ranked list of 
outcomes is displayed in Table 3.e. 
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Table 3.d: Outcomes classified as feasible or not feasible based on age-specific incidence rates estimated with 
VSD data
Estimated incidence rate of diagnosis per 100,000 person-years
Birth - Age 2 Ages 3 - 8
Feasible
All-cause morbidity Not estimated Not estimated
All-cause mortality Not estimated Not estimated
Allergy development 14,996 4,455
Anaphylaxis 2,139 1,373
Asthma development 4,481 2,688
Attention deficit disorder 13 655
Autism spectrum disorders 236 297
Bells’ Palsy 15 11
Chronic urticaria 2,453 1,415
Crohn’s disease and ulcerative colitis 6 5
Encephalopathy 16 9
Epilepsy 159 105
First demyelinating event* 4 4
Juvenile rheumatoid arthritis 9 9
Kawasaki’s disease 34 16
Learning, communication, developmental disorders 3,196 1,387
Meningitis 33 7
Seizures 1,066 209
Syncope and vasovagal reaction 66 111
Tics 52 235
Type 1 diabetes 21 25
Not feasible
Brachial neuritis 1 <1
Cataplexy and narcolepsy <1 1
Cerebellar ataxia / ataxia 5 3
Chronic fatigue syndrome 1 <1
Chronic hepatitis 4 1
Encephalitis 4 3
Infantile spasms 12 <1
Multiple sclerosis <1 <1
Psoriatic arthritis 1 <1
Systematic lupus erythematosus 1 <1
* Although first demyelinating event was initially classified as not being feasible due to low incidence, it was re-classified as feasible to study because it is a potentially 
serious outcome that was ranked highly on public concern
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Table 3.e: Ranking of outcomes on feasibility, public health significance, and public concern 
Average public 
concern ranking
Average public health 
significance ranking
Final combined rankingRanked from 1 (lowest) to 5 (highest)
1 Asthma development 4.33 4.17 8.50
2 Anaphylaxis 3.67 4.67 8.34
3 Encephalopathy 4.75 3.50 8.25
4 All-cause mortality 4.17 3.83 8.00
5 Meningitis 4.00 4.00 8.00
6 Learning, communication, developmental disorders 5.00 2.83 7.83
7 Epilepsy 4.00 3.83 7.83
8 Type 1 diabetes 4.00 3.83 7.83
9 First demyelinating event 4.17 3.66 7.83
10 Allergy development 4.17 3.33 7.50
11 Attention deficit disorder 4.67 2.83 7.50
12 All-cause morbidity 4.17 3.17 7.34
13 Crohn’s disease and ulcerative colitis 4.17 3.17 7.34
14 Syncope and vasovagal reaction 3.17 3.17 6.34
15 Seizures 3.50 2.67 6.17
16 Kawasaki’s disease 3.33 2.83 6.16
17 Juvenile rheumatoid arthritis 3.50 2.50 6.00
18 Tics 3.50 2.17 5.67
19 Chronic urticaria 2.83 2.00 4.83
20 Bells’ Palsy 2.67 1.50 4.17
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4.1 Introduction
Chapter 2 of this White Paper identified various 
methods for defining childhood vaccine exposures 
at the level of the immunization schedule. 
These included continuous measures, such as 
average days undervaccinated, and categorical 
measures, identified either from known alternative 
schedules or from data mining techniques. 
Chapter 3 covered health outcomes of interest and 
developed a priority listing of outcomes based on 
plausibility and feasibility. This chapter reviews 
key considerations for the design and analysis 
of vaccine schedule safety studies. It begins 
with a summary of key points from the methods 
expert meeting conducted as part of this paper’s 
development, and general principles derived 
from the meeting. It then discusses specific study 
design considerations, framed in terms of the 
biases that may affect immunization schedule 
safety studies in the VSD. This is followed by a 
review of the strengths and limitations of various 
study designs, and a discussion of analytic 
approaches. This chapter closes by describing 
an example study of asthma risk associated with 
different vaccine schedules, with illustrations of 
how various biases may be handled.
4.2 Summary of subject matter expert 
meeting
On June 27th, 2014, Group Health Research 
Institute hosted a meeting of VSD contributors 
and outside experts in drug and vaccine safety 
methodology. The meeting’s objectives were 
to elicit recommendations from the outside 
experts on principles and analytic approaches 
for assessing the safety of the childhood 
immunization schedule. The outside experts were 
Martin Kulldorff, of Harvard Medical School, and 
M. Alan Brookhart of the University of North 
Carolina. They were joined by Mike Jackson and 
Lisa Jackson from Group Health; Jason Glanz 
and Sophia Newcomer of Kaiser Permanente 
Colorado, and (by teleconference) David McClure 
of Marshfield Clinic Research Foundation. 
The methodology experts made a number of 
recommendations for VSD studies of vaccine 
schedule safety:
• Plan for multi-step investigations
 » Initial studies can determine outcomes 
and schedules for which an association 
exists
 » Follow-up studies can investigate 
which aspects of the schedule(s) are 
responsible for the associations
 » Initial studies should focus on identifying 
or ruling out large risks (which are less 
likely to be affected by bias) rather than 
on small increases in risk
• Defining immunization schedules
 » Continuous summary measures are 
preferable to categorizing subjects into 
groups due to increased statistical power
 » Comparing fully vaccinated children 
to totally unvaccinated children would 
likely be highly confounded
 » Data-driven methods can be used 
to create summary measures, such 
as “distance” from various defined 
schedules.
 » Alternatively, multiple measures of 
vaccination receipt and timing can be 
incorporated into a single multivariable 
regression model to assess which 
aspects of a schedule may need further 
investigation (although collinearity 
of covariates is a concern with this 
approach)
 » “Per Protocol” approach is another 
alternative for events that occur before 
the completion of the schedule
• Methods
 » Initial studies should use designs and 
methods whose properties are well-
known (cohort and case-control studies 
in particular).
 » Cohort studies can either use survival 
analysis to properly censor subjects 
when they experience events of interest, 
or define age at cohort entry such that 
exposure has occurred before entry and 
all events of interest occur after.
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• Confounding and bias
 » Focus on ruling out (or identifying) large 
effects, as small effects could more easily 
be the result of unmeasured confounding
 » It may be important to collect data 
on confounders that are not typically 
measured in administrative data, such as 
parental education
 » Measures of healthcare utilization will be 
important
 » Negative controls can be used to test for 
the presence of bias and uncontrolled 
confounding
 » Confounding due to differences in 
healthcare utilization is less likely for 
severe outcomes (i.e., those requiring 
hospitalization)
 » Restricting may be an important tool for 
controlling confounding, at the possible 
expense of generalizability
• Possible opportunities for ecological studies
 » Comparing vaccination rates and 
outcomes across clinics within the VSD 
MCOs
 » Comparing outcome rates over time (e.g., 
pre- and post-introduction of rotavirus 
vaccines)
General principles from the expert meeting
Both the White Paper VSD team and the external 
methods experts agree that the field of vaccine 
schedule safety is in its infancy. As such, we 
recommend that VSD studies should begin by 
ruling out (or identifying) large differences in 
risk of adverse events between children who 
receive the ACIP recommended vaccines vs. 
undervaccinated children. This work should be 
conducted using common study designs whose 
properties and biases are well understood. For 
most of the outcomes of interest, this would 
involve cohort studies to estimate incidence rate 
ratios or hazard ratios. For certain outcomes 
that might require confirmation via medical 
record review, case-control studies would be 
preferred. More sophisticated methods such as 
two-stage sampling,68 counter-matching,69 or 
case-only designs70 should be reserved until after 
basic methods have provided more insight into 
confounding and biases in schedule-level studies.
There is also agreement on the need to plan for 
multi-stage investigations when designing schedule 
safety studies. The first stage involves identifying 
whether an outcome of interest is associated with 
a particular schedule (or vaccination summary 
measure). If an association is detected, this should 
be followed by additional studies investigating 
what aspects of the schedule/summary measure 
are associated with the outcome. The specific 
aspects will depend on the observed association 
but will likely include timing of doses, number 
of concomitant vaccines, and/or specific vaccines 
excluded or delayed.
4.3 Study design considerations
As with any observational study, the goal of good 
design for VSD schedule-level safety studies is 
to rule out non-causal explanations for the study 
findings: chance, selection bias, information bias, 
and confounding, as well as reverse causality.71 
We first review these alternative explanations and 
their likely impacts on vaccine schedule safety 
studies. We then present a sample VSD study to 
illustrate the design considerations in practice.
Reverse causality
Reverse causality, where onset of the study 
outcome may influence the exposure (i.e. 
completion of a particular vaccine schedule), is a 
concern whenever the study outcome can occur 
prior to completion of one of the immunization 
schedules of interest. Parents may alter their 
intended immunization schedules for a child 
who experiences a negative health outcome, 
particularly if the outcome is perceived to be a 
result of a vaccine. For example, a child receiving 
vaccines according to the ACIP schedule could 
have an anaphylactic reaction following the third 
dose of DTaP vaccine. In response, the child’s 
parents or provider may defer or refuse future 
vaccine doses, so that the child does not complete 
the ACIP schedule. In schedule safety studies, 
vaccination and event times must be carefully 
measured, and subjects must be censored after 
they experience a study outcome. 
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Of greater difficulty are studies of outcomes that 
are diagnosed after the age at which the schedule 
is completed, but that have a gradual or insidious 
onset. In such cases, early signs or indications of 
disease may be apparent to the parents, who may 
alter their child’s vaccination patterns in response, 
but in advance of any clinical diagnoses. VSD 
schedule safety studies using endpoints that may 
have gradual onset should consider the possibility 
of reverse causality.
Confounding
Confounding is likely to be a serious threat to the 
validity of schedule-level safety studies. Children 
who receive the ACIP-recommended vaccines 
differ in meaningful ways from children who 
do not. Parental refusal or delay of childhood 
vaccines varies by race/ethnicity, household 
income, parental education, and household 
size, among other factors.13,52 The incidence of 
many safety outcomes of interest also varies by 
these factors. Incidence of physician-confirmed 
asthma, for example, varies by race/ethnicity, 
number of siblings, and household socioeconomic 
status (often mediated through differences in 
environmental exposures), among many other 
factors.72,73 Any studies of vaccine schedule 
and risk of incident asthma in children will be 
potentially confounded by these factors. 
A particular challenge for vaccine schedule safety 
studies is that many potential confounders are 
difficult to measure using EHR data. Household 
size and socioeconomic status, for example, are 
very difficult to capture based on administrative 
data. Linking enrollees together based on insurance 
plans or addresses can give approximate measures 
of household size but will miss any household 
members who have different insurance plans, 
and do not include any measure of household 
density. Careful consideration must be given 
to identify potential confounders that must be 
measured, perhaps through the use of causal 
models such as directed acyclic graphs (DAGs),74 
prior to beginning any schedule safety study. In 
a causal DAG, the investigator describes variables 
(nodes) representing exposure and outcome, 
and covariates that the investigator believes to be 
causally related to exposure and outcomes. The 
investigator connects these nodes using arrows to 
represent the expected direction of causal action. 
For example, if maternal education is expected to 
affect childhood vaccination, the investigator would 
draw an arrow from the “maternal education” node 
to the “childhood vaccination” node. After the 
investigator has used the DAG to describe all of 
the assumptions about the relevant variables, the 
DAG can be used to identify potential confounders 
and variables whose control can reduce 
confounding in estimates of the exposure-disease 
association. Use of these causal models can help 
investigators identify whether key confounders 
can be controlled for by administrative healthcare 
data, whether additional data collection will be 
necessary, or whether important confounders may 
be unmeasurable.
Given the expected difficulties in measuring 
potential confounders, we recommend that VSD 
studies of vaccine schedule safety incorporate 
methods to detect the influence of uncontrolled 
confounding. One feasible approach is to analyze 
the association between the vaccine schedule 
and one or more “control” outcomes.75 In this 
context, control outcomes are diseases that 
have no expected causal association with the 
vaccine schedule. If a study finds an apparent 
association between the vaccine schedule and 
the control outcome(s), this is evidence that 
important differences exist in baseline health 
status, socioeconomic status, healthcare utilization, 
or other covariates between exposure groups, 
suggesting that uncontrolled confounding may 
be present in the main study results. Depending 
on the outcome under study, possible control 
outcomes could include injuries, well-child visits, 
or neoplasms.
To illustrate, minor injuries might be a useful 
control outcome for safety studies where 
the outcome would typically not require 
hospitalization. These might be defined as 
outpatient visits with an ICD-9-CM code of 
800-829 (fractures), 840-848 (sprains and 
strains), or 940-949 (burns) for which there 
is no hospitalization for similar codes within 
the two preceding or following months. There 
is no plausible biologic pathway by which 
vaccines could cause these minor injuries. Any 
association between immunization schedule and 
minor injuries must be due to confounding from 
sociodemographic factors that put some children 
at an increased risk of minor injuries, or to 
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parental healthcare seeking preferences for non-
emergency conditions. A priori we might expect 
that confounding due to parental preferences for 
healthcare utilization might be similar for minor 
injuries as for outcomes such as allergies, asthma, 
or attention deficit disorder, making minor injuries 
a potential control outcome for these outcomes. 
VSD investigators could use a retrospective 
cohort study to assess whether minor injuries are 
appropriate control. 
To illustrate with incident asthma in children 
2-4 years of age as the safety outcome of 
interest, the population would consist of all 
children enrolled in the VSD from birth through 
23 months of age who were fully vaccinated 
according to the ACIP schedule. These children 
would be stratified into groups based on 
measurable sociodemographic data (e.g., census 
tract, race/ethnicity) and healthcare utilization 
(e.g., number of outpatient visits prior to the 
second birthday). Children would be followed 
from their second birthday until the earliest 
of MCO disenrollment, death, or their fifth 
birthday. The investigators would calculate 
the rates of incident asthma and of incident 
minor injury within each sociodemographic/
utilization stratum. If this incidence rate ratio is 
the same across strata, this suggests variations in 
sociodemographics and utilization have similar 
effects on incident diagnoses of asthma and 
minor injuries, independent of vaccination history 
(since all children are fully vaccinated). Under 
the assumption that vaccination does not impact 
minor injuries, this would be evidence that minor 
injuries are an appropriate control outcome for 
asthma. 
Information bias
Information bias results whenever exposures, 
outcomes, or model covariates are measured 
imperfectly. Misclassification of vaccination 
history or covariates that is non-differential with 
respect to the outcomes will tend to bias effect 
estimates towards the null. The same is true for 
misclassification of outcomes or covariates that is 
non-differential with respect to vaccine history. 
Differential misclassification, in contrast, can bias 
effect estimates either toward or away from the 
null.
In vaccine schedule safety studies, a particular 
concern is differential misclassification of 
outcomes and covariates based on vaccination 
history. Children who are undervaccinated due 
to parental choice have lower rates of healthcare 
utilization (both outpatient visits and emergency 
department encounters) than fully vaccinated 
children.3 Differential healthcare utilization 
between fully vaccinated and undervaccinated 
children has several consequences for information 
bias. First, data on covariates such as body 
mass index and comorbid illnesses may be less 
available for undervaccinated children than 
for fully vaccinated children. This can lead to 
differential misclassification of covariates, such 
as greater missing data among undervaccinated 
children or falsely considering undervaccinated 
children to be disease-free with respect to 
comorbidities of interest. 
Second, differences in healthcare utilization mean 
that adverse outcomes may be less likely to be 
detected in undervaccinated children compared to 
fully vaccinated children. Severe adverse outcomes 
may be detected later in undervaccinated children, 
if parents delay seeking healthcare or specialty 
care to confirm possible diagnoses. Delayed or 
missing outcome data in undervaccinated children 
will falsely reduce the observed incidence in 
these children, biasing effect estimates such that 
undervaccination appears safer than it truly is.
Several general approaches can be used to reduce 
the problem of differential misclassification 
between fully vaccinated and undervaccinated 
children. First, study populations can be restricted 
to children for whom similar information is 
likely to be available in EHRs and administrative 
databases, perhaps by matching fully and 
partially vaccinated children on the number of 
well-child visits or total outpatient visits they 
have as of a specified age. This could be done 
by setting some minimum utilization criteria 
for all study participants, such as restricting the 
study population to children who have been 
continuously enrolled since birth and who have 
had at least, for instance, three MCO outpatient 
visits during the first year of life. Alternatively, 
the investigators could match fully vaccinated 
subjects to undervaccinated subjects on number of 
outpatient medical encounters. 
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Where restriction is not possible, attempts 
should be made to define the sensitivity/
specificity or medical record confirmation rate 
of the measured outcome and key covariates 
in fully vs. undervaccinated children (perhaps 
through a limited medical record review, although 
such records may not contain the necessary 
information). These can be used to correct effect 
estimates for misclassification.76,77 or, at a minimum, 
perform sensitivity analyses to put bounds on the 
error due to misclassification.
Selection bias
VSD cohort studies are relatively resistant to 
selection bias, as the study population generally 
includes all members of the enumerated VSD 
population who meet some eligibility criteria, 
independent of exposure or outcome status. 
Selection bias in VSD vaccine schedule safety 
studies can be minimized by ensuring that all 
exclusion criteria are applied equally to fully 
vaccinated and undervaccinated children (in cohort 
studies) or to cases and controls (in case-control 
studies). As a simplistic example, consider a study 
comparing children vaccinated according to the 
ACIP schedule (where all doses are completed 
by 18 months of age) with unvaccinated children. 
The investigators might want to reduce possible 
information bias due to apparently unvaccinated 
children actually receiving vaccines outside 
the VSD MCOs. For this, they might exclude 
unvaccinated children who had fewer than four 
outpatient visits during the first two years of life. If 
they do not also exclude fully vaccinated children 
with fewer than four outpatient visits during the 
first two years of life, selection bias could be 
introduced into the study. Since unvaccinated 
children are selected to be more frequent users of 
the MCO than vaccinated children, outcome rates 
may appear to be higher in unvaccinated children 
than vaccinated children due to this selection 
rather than to a true vaccine effect.
Chance
Random chance is ruled out as an explanation 
for study findings when studies are adequately 
powered to detect the effect size of interest. Power/
sample size calculations should be performed 
before beginning any VSD study. To provide some 
general guidance on the feasibility of certain types 
of studies, this section presents detectable effect 
sizes for some hypothetical studies of vaccine 
schedules and various outcomes of interest.
A current VSD study on vaccine ingredients43 
defined a cohort of VSD children born between 
2004 and 2011 who were continuously enrolled 
from 2 to 24 months of age, had more than one 
outpatient visit during that time, and received no 
vaccines for which the manufacturer was unknown. 
This cohort consisted of 303,070 children. Of 
these, 152,871 (50.9%) were fully vaccinated 
according to the ACIP schedule, 5,492 (1.8%) were 
vaccinated consistent with a defined alternative 
schedule, 3,404 (1.1%) had no vaccination records 
in the VSD databases, and 1,898 (0.6%) had no 
vaccines and at least one V-code for vaccine refusal. 
Based on this cohort, we estimated the minimum 
detectable incidence rate ratios from a cohort study 
comparing rates of events after two years of age 
in the fully vaccinated children to either children 
following a defined alternative schedule or to 
unvaccinated children with a V-code for refusal. In 
this design we assume that unvaccinated/partially 
vaccinated children are matched 1:10 with fully 
vaccinated children based on variables such as 
number of outpatient visits.
The preliminary calculations shown in Table 4.a 
suggest that studies of adverse events in children 
vaccinated according to the ACIP schedule 
compared to unvaccinated children or children 
vaccinated with an alternative schedule should 
be well powered to detect meaningful differences 
in risks of common events. These power 
calculations did not take into account any potential 
for confounding. For a given outcome, direct 
adjustment or cohort restriction may be necessary 
to address confounding. These power calculations 
should therefore only be used as a general guide. 
The incidence of asthma development and allergy 
development all exceed 1,000 per 100,000 person-
years in VSD children 3-8 years of age. For such 
outcomes, VSD studies with two or more years 
of follow-up can detect 30% increases in risk 
associated with the ACIP schedule relative to other 
specific schedules. In contrast, VSD studies may 
only be able to rule out large differences in risk for 
rare outcomes such as meningitis, encephalopathy, 
and development of type I diabetes, which have 
incidence of <30 per 100,000 person-years in 
children 3-8 years of age. 
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Table 4.a: Minimum detectable incidence rate ratios (IRR) at different expected incidence rates in comparison 
children and durations of follow-up, assuming 80% power, 25% annual loss to follow-up, and a Type I error rate 
of 0.05
Incidence per 100,000 person-years in 
comparison group Comparison group
Minimum detectable IRR assuming:
Five years of follow-up Two years of follow-up
1,000 Alternative schedule 1.24 1.33
1,000 Unvaccinated 1.44 1.6
100 Alternative schedule 1.9 2.26
100 Unvaccinated 2.75 3.56
10 Alternative schedule 5.19 7.42
10 Unvaccinated 10.66 16.43
5 Alternative schedule 8.16 12.28
5 Unvaccinated 18.37 29.38
4.4 Study designs: strengths and limitations
Case-control, cohort, risk-interval, and ecological 
designs have all been used in assessments of 
vaccine safety. Each design has advantages and 
disadvantages that make it more or less fit to 
specific vaccine safety questions. The general 
strengths and limitations of basic epidemiological 
study designs will not be discussed here, as they 
have been extensively covered in numerous 
sources.78,79 Rather, this section discusses the 
strengths and limitations of these designs relative 
to possible sources of bias in vaccine schedule 
safety studies conducted in the VSD.
Cohort studies
Cohort designs are often the design of choice for 
VSD studies,80-82 particularly those requiring only 
administrative healthcare data. Cohort designs 
offer several advantages for studying vaccine 
schedule safety. Because the VSD population is 
fully enumerated, with detailed data on MCO 
enrollment, VSD cohort studies typically avoid 
problems of selection bias, so long as all eligibility 
restrictions are applied equally to all study subjects 
regardless of exposure status. When steps are taken 
to ensure that cohort members are disease-free as 
of the start of follow-up, cohort studies with careful 
attention to exposure times and with appropriate 
censoring avoid problems of reverse causality. 
Cohort studies are also very well suited to the 
use of control outcomes, which are likely to be of 
considerable importance for detecting residual bias 
and confounding. Another benefit of cohort studies 
is ease of calculation of attributable risk, which is 
often an important metric for policy-making. 
Cohort designs are, of course, more difficult for 
studies that may require primary data collection 
on all study subjects via surveys, medical record 
reviews, or other measurements. Due to the 
potential information biases when comparing fully 
vaccinated children to undervaccinated children 
who lack an ICD-9-CM code for vaccine refusal, 
there may be many safety questions of interest 
that require additional data collection to overcome 
information biases. Cohort studies have limited 
utility for these situations. 
Case-control studies
Case-control studies are less common than cohort 
studies in the VSD, but they are used occasionally.83 
For vaccine schedule safety studies, case-control 
studies are likely to be of use when information 
biases would result from relying solely on 
administrative healthcare data and additional data 
collection is needed. As an example, a study could 
identify children diagnosed with a health outcome 
(for example, Type 1 diabetes) between ages 3 and 
8 and match them to children without that health 
outcome. Then, researchers could look back and 
determine whether each child was fully vaccinated 
per ACIP recommendations or whether they were 
on an alternative vaccination schedule. Primary 
data collection may be necessary since complete 
immunization histories may not be available for 
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cases or controls who enrolled in their MCO 
later in childhood. In that study, it may also be 
important to conduct medical record reviews or 
parental surveys of children apparently following 
the alternative schedule, to verify that the children 
were not receiving vaccines outside of the VSD 
MCOs. The cost of additional data collection is 
typically more feasible in a case-control design 
than in a cohort design. 
Case-control designs tend to be more susceptible 
to selection biases than cohort designs. Choosing 
an improper control group in particular can often 
lead to selection biases in case-control designs. 
Within the VSD, some of the typical problems of 
control selection (such as selecting appropriate 
control groups from hospitals with uncertain 
catchment areas) may be reduced because the case-
control sample is nested in an enumerated cohort. 
Case-control studies are also more susceptible to 
errors of reverse causality than cohort studies, and 
require careful definitions of outcome onset times 
and exposure periods. Due to the challenges of 
studying multiple outcomes in a case-control study, 
control outcomes to detect bias are difficult to use 
with case-control designs.
Risk-interval designs
Self-controlled case series and other similar risk-
interval methods have been used with increasing 
frequency in the VSD.59,64 Self-controlled designs 
are well suited to control for confounding due 
to time-invariant factors, and greatly reduce 
problems with selection bias from sampling cases 
and controls or from defining groups based on 
exposure history. However, self-controlled designs 
have two main disadvantages for vaccine schedule 
safety studies. First, self-controlled designs are best 
suited to events occurring in a short risk window 
following exposure.84 In contrast, many of the 
schedule safety outcomes of interest occur months 
or years after the completion of the vaccination 
schedule. Second, self-controlled designs have 
generally been applied to exposures that occur 
over a short period of time, such as an individual 
vaccination or a cellular telephone conversation.85 
Little work has been done on the use of risk-
interval designs with long-term exposures such as 
vaccination schedules. 
Another design recently developed for VSD studies 
is the case-centered approach. This design is not 
self-controlled, and it relies on examining risk 
intervals for the exposure (vaccination) rather than 
the outcome. With the case-centered design, the 
observed odds of vaccination during a time interval 
before an outcome is compared to the expected 
odds of vaccination in that same interval.82 Like 
other risk interval methods, application of this 
method has not been extended to studies of entire 
immunization schedules and long-term outcomes.
Ecological studies
The external experts suggested several possible 
ecological studies that could be conducted to 
examine vaccine schedule safety. One suggestion 
was to compare rates of adverse events between 
countries that have different recommended 
vaccination schedules. This type of comparison is 
outside the scope of the VSD and is not considered 
further here. A second suggestion was to compare 
rates of adverse events within the VSD population 
from different time periods. For example, event 
rates from 2005-2006 could be compared to event 
rates from 2007 and after to assess the impact of 
the addition of rotavirus vaccines to the schedule.86 
ACIP has made relatively few additions to the 
recommended vaccines for children <2 years of age 
in the past decade (rotavirus, universal influenza 
vaccine,86 switch to PCV13 from PCV787), which 
limits the schedule safety questions that can be 
answered with time-based ecological studies.
A third suggestion was to compare adverse event 
rates for clinics within the VSD MCOs. Pediatricians 
and family medicine physicians vary in the degree 
to which they encourage adherence to the ACIP 
schedule among their patients.89 If there is clinic-
level variation in the promotion of the ACIP 
schedule, there may be clinic-level variation in 
childhood immunization and in corresponding 
rates of adverse events. There may also be clinic-
level variation in diagnosis of outcomes; for 
example, variations in prevalence of referrals for 
neurodevelopmental assessment. A clinic-level 
ecological study may be feasible within the VSD. To 
assess feasibility, a preliminary study could assess 
whether there is clinic-level variation in vaccination 
summary measures such as days undervaccinated, 
and whether the variability is exists across clinics 
within an MCO or only across MCOs. These types 
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of group-level studies are prone to ecologic fallacy 
and bias from confounding, and such studies 
should be approached with caution. 
4.5 Analytic methods
Precise analytic methods for any vaccine schedule 
safety study will depend on the exposures and 
outcomes of interest, the study design, and the 
study population, among other factors. With 
that in mind, this section provides some general 
guidance for study analysis.
Statistical methods and effect measures of 
interest
In cohort studies, the effect measures of interest 
for causal inference are generally either hazard 
ratios, incidence rate ratios, or risk ratios. The 
choice of effect measure depends on scientific 
interest, on available data, on the assumptions 
deemed to be reasonable by the investigators, 
and (to some degree) on computational power. 
Where individual-level data are available on 
entry, event, and censoring times, and where 
proportional hazards can be assumed (or 
deviations from proportional hazards can be 
modeled) investigators can estimate hazard ratios 
using Cox regression models. These will likely be 
the most common data for vaccine schedule safety 
studies, as careful attention will need to be given 
to exposures times and dates of start and stop of 
follow-up to avoid reverse causality.
With similar data but when the proportional 
hazards assumption is not met, or where 
the population size makes Cox regression 
computationally intractable, incidence rate ratios 
can be estimated using Poisson or negative 
Binomial regression models. Incidence rate ratios 
can also be estimated when only aggregate data 
on person-time and events are available, although 
this is rarely a limitation in VSD studies. Due to 
detailed person-level data available on the VSD 
population, it is uncommon for VSD studies to 
have only data on the fact of an event without 
the corresponding person-time at risk. In this 
event, however, risk ratios can be calculated 
using Poisson regression with robust variance 
estimates89 or via log-binomial regression.
Case-control studies typically involve estimating 
odds ratios to estimate (when using incidence 
density sampling) or approximate (when using a 
cumulative design) risk ratios.79 Odds ratios are 
generally estimated using logistic regression models.
Models for exposure
As discussed above, vaccine exposures can either 
be modeled by grouping subjects into categories 
(perhaps defined by data mining techniques) 
or by using continuous summary measures of 
exposure or by deviation from specific schedules. 
If we conduct a cohort study of outcome risk 
using a categorical exposure measure, we might 
collapse subjects into categories based on 
exposure categories and covariates and calculate 
total events and person-time in each category. In 
this approach, each unique vaccination schedule 
would be represented by a binary covariate 
indicating whether a subject was compliant (=1) 
or not (=0) with that particular schedule. 
To illustrate, consider a study comparing the 
incidence rate of some event in children 2-3 years 
of age between children who are fully vaccinated, 
children who are unvaccinated, and children 
vaccinated according to “Dr. Bob’s selective 
schedule.”28 In this study, incidence rate ratios 
could be estimated using a Poisson regression 
model such as this:
log(E(Y|x_1,x_2,z))=α+β
1
ACIP+β
2
Dr.Bob+βz+log(pt)
where Y is the count of events, z is a vector of 
covariates, and pt is person-time. The ACIP and 
Dr.Bob variables indicate compliance with either 
the ACIP or Dr. Bob’s selective schedules, with 
unvaccinated children serving as the reference 
group. The parameters β
1
 and β
2
 are the log rate 
ratios for the ACIP schedule or Dr. Bob’s selective 
schedule, respectively, relative to no vaccination. 
Note that, if the study design involved following 
children for outcomes that could occur prior to 
the completion of the schedule, it is possible 
that a subject could be compliant with more than 
one vaccination schedule at some time point. For 
example, multiple categories might involve giving 
no doses prior to one year of age. For follow-up 
time prior to one year of age, subjects receiving 
no vaccines would be classified as compliant with 
all such schedules.
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Alternatively, we may conduct a study using 
a summary measure such as average days 
undervaccinated (ADU). Consider conducting a 
survival analysis for time to first event, with ADU 
as the primary exposure of interest. Hazard ratios 
could be estimated from a model such as:
log(E(λ(t|ADU,z)))=log(λ_0 )+β
1
ADU+βz
where λ(t) is the hazard function and λ
0
(t) is the 
baseline hazard. In this model, β
1
 is the log hazard 
ratio for a one-unit increase in ADU. This model 
assumes that there is a linear relationship between 
ADU and log(λ(t)). In practice, the association 
between ADU and outcome may not be expected 
to follow a linear function. In that case, ADU 
could be parameterized using a polynomial or 
spline function, or by dividing ADU into clinically 
relevant categories and including these as a set of 
binary variables in the model. 
Sensitivity analyses for misclassified data
As mentioned above, measurement error in 
vaccination history, important confounders, or 
outcomes can bias study results. Collecting data 
using gold-standard measurements (such as 
medical record review or interview with parents) 
is, naturally, the most effective method for reducing 
measurement error. However, it is often impractical 
or impossible to collect data on all study subjects 
using these labor-intensive methods. Another 
approach to possible information bias is to first 
quantify the measurement error present in the 
administrative data (through surveys or medical 
record reviews conducted within the VSD MCO 
populations). 
To illustrate the additional data collection, 
consider important covariates such as parental 
education or household socioeconomic status. 
These are generally not captured by administrative 
healthcare data and must either be measured 
using separate surveys or by proxies such as 
census tract data. A proposed study to estimate 
misclassification associated with use of census 
tract data is to conduct a cross-sectional survey 
of VSD households. For this, VSD investigators 
would select a random sample of children in the 
VSD population as of the study start data, with 
block randomization based on some measures of 
census tract characteristics such as median income. 
Surveys would be sent to these households, 
requesting data on key features such as race/
ethnicity, parental education, and measures of 
socioeconomic status. The investigators would then 
estimate the sensitivity and specificity of census 
tract data for these factors, relative to the gold 
standard of self-reported data.
Alternatively, VSD investigators could conduct a 
systematic literature review and meta-analysis of 
published studies on the accuracy of census tract 
data relative to individual-level data. This approach 
may provide more comprehensive data and greater 
statistical power than a survey conducted within 
the VSD. However, it has the limitation of not 
being specific to the VSD population, making 
extrapolation to VSD studies uncertain.
After quantifying the expected degree of 
misclassification, these quantifications can be 
used to adjust the effect estimates of interest 
for the presence of misclassification.90 Where 
this is not feasible, the measurement error data 
can still be used to put bounds on the effects 
of misclassification, via sensitivity analyses or 
simulation studies.
One approach to simulation studies for 
misclassification is to create simulated datasets 
of the study population. These simulated dataset 
are based on the observed study data, but with 
the exposure, outcome, or covariate data of the 
simulated subjects randomly altered based on 
estimates of misclassification in the observed 
data.91 Consider a study comparing fully vaccinated 
children to unvaccinated children, so defined 
based on MCO vaccination records. Suppose that 
analyses of VSD populations suggested that 20% 
of apparently unvaccinated children had in fact 
received all the recommended vaccines, but outside 
the MCOs, and so were actually fully vaccinated. 
The investigators could then simulate a series 
of datasets. In each dataset, simulated subjects 
would be randomly sampled from the observed 
study populations. Sampled unvaccinated subjects, 
would randomly be classified as vaccinated 
(using, for example, Monte Carlo methods).92 The 
association between vaccination and outcome 
would be estimated in each simulated dataset. The 
median (2.5th, 97.5th percentiles) estimate from the 
simulated datasets would represent the expected 
association (with 95% confidence limits) accounting 
for the misclassification.
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Sensitivity analyses could also be used to put 
bounds on the expected effects of misclassification 
on study results. Using the example of 20% 
misclassification of unvaccinated subjects above, 
investigators could repeat the study analyses but 
reassigning 20% of the unvaccinated children to 
the fully vaccinated category. The bounds of the 
effect of misclassification could be estimated by 
first reclassifying only children who experienced 
the outcome of interest (moving effect estimates 
maximally toward a beneficial effect of 
unvaccination), and then by reclassifying only 
children who did not experience the outcome 
(moving effect estimates maximally toward a 
beneficial effect of vaccination).
Healthcare utilization: design and analysis 
methods
Differences in healthcare utilization between 
fully vaccinated and undervaccinated children 
poses particular problems for vaccine schedule 
safety studies. As discussed in the information 
bias section, one concern is the potential for 
information bias due to differences in utilization. 
Several options are available to handle differences 
in utilization. Perhaps the most effective would 
be to restrict the study population on the basis 
of healthcare utilization, though this may limit 
generalizability. 
4.6 Sample proposed study: Vaccine 
schedule and risk of asthma
Asthma was highly ranked as an outcome of 
public health significance by the VSD White Paper 
team and external experts (Table 3.e). With an 
estimated incidence of 2,688 cases per 100,000 
person-years among children 3-8 years of age, 
studies within the VSD should be adequately 
powered to detect meaningful differences in 
risk of asthma between children vaccinated 
according to the ACIP schedule and three separate 
comparison groups:
• Fully unvaccinated children
• Children vaccinated according to “Dr. Bob’s 
Alternative Schedule” or “Dr. Bob’s Selective 
Schedule”28
• Children vaccinated according to a shot-
limiting schedule during the first year of life
The aim of this study is to estimate the association 
between the childhood vaccine schedule during 
the first two years of life and risk of developing 
asthma in the third and fourth years of life.
Study population
The proposed study population consists of 
VSD enrollees born from 2006–2011, who are 
continuously enrolled from 2 to 23 months of age, 
and have more than one outpatient visit before 
24 months of age. The restriction to continuous 
enrollees and those with multiple outpatient 
visits is intended to exclude children who may 
be receiving vaccines outside of the VSD medical 
systems or their associated state immunization 
information systems. This reduces information 
bias by reducing misclassification of vaccination 
history. Requiring enrollment through 23 months 
of age gives all study subjects the opportunity to 
fully comply with the ACIP schedule (which must 
be completed before 2 years of age) and schedules 
defined in The Vaccine Book by Dr. Bob Sears, 
which must be completed by 19 (Alternative) or 16 
(Selective) months of age.28 This reduces selection 
bias by applying the same eligibility criteria to all 
study subjects. Subjects with an ICD-9 code for 
asthma prior to 24 months of age will be excluded. 
This exclusion avoids reverse causality that could 
result if incident asthma alters the vaccination 
schedule a child would otherwise have received. 
Exposure groups
Fully unvaccinated children will be identified as 
having no recorded vaccines from birth through 
23 months of age and who also have at least one 
ICD-9-CM code for vaccine refusal (V64.05 or 
V64.06) prior to 24 months of age. Children with a 
vaccination pattern consistent with the Alternative 
schedule from The Vaccine Book by Dr. Robert Sears 
will be identified by receipt of the first three doses 
of pneumococcal and Hib vaccines on the same day, 
but on a different day than the first three doses of 
DTaP. Children with a vaccination pattern consistent 
with the Selective schedule from The Vaccine Book 
will be identified by the absence of Hepatitis B, 
polio, MMR, or varicella vaccines (but at least one 
recorded dose of another vaccine).28 Children on a 
consistent shot-limiting schedule will be identified as 
those children who received 2 or few vaccinations 
at all immunization visits before age 2 years,30 but 
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who do not appear to be following the Alternative 
schedule as described above. 
Each child in a comparison group (unvaccinated, 
“Dr. Bob”, or shot-limiting) will be matched to ten 
fully vaccinated children based on birth year and 
the number of outpatient visits during the first 12 
months of life. Matching on number of outpatient 
visits helps restrict the study population to children 
with similar patterns of healthcare utilization. This 
reduces information bias by reducing differential 
misclassification of outcomes between fully 
vaccinated children and comparison children. It 
also reduces confounding due to factors that are 
correlated with healthcare utilization. Matching 
on year of birth reduces confounding due to any 
potential secular changes in vaccination patterns 
and in asthma incidence.
Follow-up and outcomes
The outcome of interest is first diagnosis of asthma, 
defined as incident diagnosis of ICD-9-CM code 
493 between 24 and 48 months of age. Subjects 
will be followed from their second birthday until 
the earliest of: death, disenrollment from their VSD 
MCO, first diagnosis of asthma, fourth birthday, 
or the end of the study on December 31st, 2015. 
The end of the study is chosen so that all study 
subjects will have equal opportunity for two full 
years of follow-up after their second birthday. 
This prevents possible information bias that could 
result if follow-up time is differential by birth year. 
Censoring subjects at MCO disenrollment prevents 
information bias from outcomes that may not be 
detected among subjects who are no longer MCO 
members. Censoring subjects after death or first 
diagnosis of asthma prevents selection bias that 
would result if subjects no longer at risk of first 
asthma were allowed to contribute further person-
time to the analysis.
Covariates
For this project, data on covariates are collected 
in order to measure and control for potential 
confounders. Identification of covariates is 
guided by a DAG (Figure 4.a). Assuming that 
a DAG adequately captures the relevant causal 
associations, the DAG can be used to identify 
which variables should be controlled for (by 
matching, restriction, or adjustment) to remove 
confounding between the exposure and the 
outcome of interest. In the hypothetical DAG of 
Figure 4, controlling for parental care-seeking 
preferences, parental education, and family 
income would be sufficient to reduce confounding 
in the estimate of the association between vaccine 
schedule and asthma risk (Figure 4.a). This is 
because control of these factors leaves no open 
“backdoor” paths from exposure to outcome 
through which confounding could operate.
In practice, none of these three factors are directly 
captured in automated data that are readily 
available in the VSD. Instead, the investigators 
must rely on proxy measures that, ideally, will 
be well correlated with the true confounders of 
interest. For example, neighborhood of residence 
may be correlated with income and education, 
so census-block data on socio-economic factors, 
linked via geocoded subscriber addresses, 
may be a partial proxy for household income 
and education. Number of well-child visits, or 
vaccination history of older siblings, may be a 
proxy for parental care-seeking preferences.
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Figure 4: A) Directed acyclic graph of predictors of vaccine schedule receipt and risk of asthma in children;  
B) Graph illustrating removal of backdoor paths from vaccine schedule to measured outcome
Analysis
Univariate statistics will describe the distribution 
of exposures, outcomes, and covariates in the 
study population. Bivariate statistics will describe 
the distribution of covariates by exposure and by 
outcome, and distribution of outcomes among 
the exposure groups. Length of follow-up will 
be calculated for each subject, beginning at the 
second birthday and continuing until the earliest 
of death, MCO disenrollment, end of the study, or 
incident asthma diagnosis. Follow-up should be 
started at the second birthday rather than at the 
start of the vaccination schedule. The schedules 
begin at different ages, so starting follow-up at 
the start of vaccination would introduce immortal 
time bias in favor of the schedule with the earliest 
age at first vaccination.93
Assuming the number of covariates is manageable, 
the population will be stratified into mutually 
exclusive groups based on unique combinations 
of exposure category and study covariates. Within 
each group, total person-time and number of 
events will be calculated. Incidence rate ratios 
for asthma in the fully vaccinated group vs. each 
comparison group will be calculated, adjusted for 
the covariates, using Poisson or Negative Binomial 
regression as appropriate. If the number of 
covariates (or number of levels of covariates) is too 
large, Cox regression could be used to estimate the 
corresponding hazard ratios. 
Vaccine schedule Incident asthma (True outcome) 
Parental care-seeking 
preferences 
Asthma diagnosis 
(Measured outcome) 
Family income 
Parental 
education 
Family socio-
economic status Environmental exposures 
Family health 
insurance Race/ ethnicity 
Vaccine schedule Incident asthma (True outcome) 
Parental care-seeking 
preferences 
Asthma diagnosis 
(Measured outcome) 
Family income 
Parental 
education 
Family socio-
economic status Environmental exposures 
Family health 
insurance Race/ ethnicity 
A 
B 
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Chapter 5: Summary and Recommendations
In this White Paper, we provided a comprehensive 
assessment for how the VSD could be used to 
study the safety of the recommended childhood 
immunization schedule. Guided by subject matter 
expert engagement, we outlined a 4 staged 
approach for identifying exposure groups of 
undervaccinated children, developed a list of 20 
prioritized outcomes, and described various study 
designs and statistical methods that could be used 
to assess the safety of the schedule. 
It is important to re-emphasize that defining 
patterns of undervaccination and alternative 
immunization schedules is complex. There 
are numerous reasons why children may be 
undervaccinated in the VSD data, including 
parental choice, missing vaccine data, barriers to 
care, gaps in insurance, or receiving their vaccines 
outside of the MCO. For these reasons, there are 
numerous different patterns of undervaccination 
in the VSD, and the potential for misclassification 
of vaccination data among undervaccinated 
children is relatively high. While it is possible 
to identify groups of undervaccinated children 
in which misclassification would be minimized 
– such as those with an ICD-9 code for vaccine 
refusal – these groups are small in number and 
would therefore lead to low statistical power in 
studies of uncommon outcomes. To address the 
potential for misclassification, we recommend 
primary data collection, but this requires 
additional resources and could significantly 
increase the timeline of a study. We also described 
a data driven approach for identifying patterns 
of undervaccination, but this would likely result 
in exposure groups that are not as clinically 
meaningful as groups of children on known 
alternative schedules. All of these factors need to 
be carefully considered when designing future 
studies of the safety of the schedule.
We used a rigorous, systematic approach for 
identifying potential outcomes for future safety 
studies. We engaged subject matter experts, and 
our assessment of the feasibility of studying 
outcomes relative to the schedule as a whole was 
based on age-specific incidence rates calculated 
directly from the VSD databases. However, it is 
also important to stress that our methods for 
prioritizing outcomes were somewhat subjective. 
Our rankings of public health significance and 
public concern, as an example, were based on our 
research experience, existing literature, clinical 
experiences and clinical judgment. Some of the 
outcomes that ranked highly on public health 
significance and public concern were particularly 
rare in children and had to be combined into 
groupings of similar conditions so that they 
would be feasible to study. However, it is not 
entirely clear that these groupings are clinically 
appropriate. First demyelinating events is an 
example of one disease grouping; if deemed by 
the CDC to be important outcome to examine, 
it would be advisable to consult with specialists 
(e.g., pediatric neurologists) to adequately define 
and adjudicate cases for a specific study. It is 
also important to note that the prioritization of 
outcomes may change over time, based upon 
new knowledge, public concern, or changing 
incidence.
Throughout the IOM report, it was implied that 
public stakeholders were primarily concerned with 
long-term outcomes, such as asthma, autoimmune 
diseases, and neurologic conditions. In response 
to the report, our outcomes assessment focused 
on conditions diagnosed in children older than 2 
years of age, representing months to years after 
the primary infant immunization series has been 
completed. Such long-term outcomes will, in turn, 
allow us to evaluate the childhood immunization 
schedule as a whole. In contrast, short-term acute 
outcomes occurring before 2 years of age pose 
challenges to studying the safety of the entire 
schedule because they are typically associated 
with short risk periods following specific vaccines, 
doses or combinations of vaccines. Short-term 
acute outcomes may also influence parents’ future 
vaccine decisions and lead to reverse causality – a 
potential source of bias described in chapter 4. 
As shown in chapter 4, there are numerous 
considerations when deciding on study designs 
and analytic plans to examine the schedule. 
In addition to reverse causality, studies of the 
schedule may be susceptible to misclassification, 
confounding and selection bias. These sources 
of bias stem from the fact that undervaccinated 
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children likely differ from age-appropriately 
vaccinated children by several important variables, 
including baseline health status, socioeconomic 
status, parental education, race/ethnicity, health 
care utilization, and family history of illness. Such 
differences are problematic because many of these 
variables are not routinely collected in the VSD 
databases. We therefore encourage investigators to 
strongly consider using the methods highlighted 
in chapter 4, including DAGs, control outcomes, 
restriction/matching, primary data collection, and 
sensitivity analyses. 
This White Paper has some notable limitations. 
First, we only engaged 5 subject matter experts to 
help develop the content. However, it is important 
to stress, however, that our SMEs were highly 
regarded experts in the fields of vaccine science 
and applied statistical methods, and it is unclear if 
our findings would have changed had we engaged 
a larger group of subject matter experts. Second, 
we did not engage any parents or parental groups 
throughout the process. While parental input 
could have affected our results, the White Paper 
was heavily informed by the 2012 IOM report 
which incorporated a rigorous public stakeholder 
engagement process. Lastly, the IOM report 
questioned the VSD’s representativeness, and we 
did not explore this potential limitation of the 
VSD in the White Paper. 
Despite the limitations described above, it 
appears feasible to study the safety of the 
childhood immunization schedule within the VSD. 
This finding is consistent with the IOM report 
conclusion that the VSD represented one of the 
nation’s best resources for studies of this nature. 
We believe that VSD investigators can use this 
document when designing and conducting studies 
of the safety of the childhood immunization 
schedule. 
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Appendix 2.a: Criteria used to evaluate days under-vaccinated for 8 recommended early childhood vaccines 
and calculation for maximum average number of days undervaccinated
Vaccination 
dosea,b
Recommended age per 
ACIP (months)
Minimum acceptable 
age (days) allowing for 
4 day grace period
Minimum acceptable 
interval between doses 
(days) allowing for 4 
day grace period
Age in days when count 
for undervaccination 
initiated
Maximum possible 
days undervaccinated 
at 730 days (no doses 
received)
Hepatitis B 730-92=638
Dose 1 0-2 0 93
Dose 2 1-4 24 24 154
Dose 3 6-18 176 38c 580
Rotavirus 252-92=160
Dose 1 2 38 93
Dose 2 4 66 24 154
Dose 3 6 94 24 215
Diphtheria, tetanus, and pertussis (DTaP) 730-92=638
Dose 1 2 38 93
Dose 2 4 66 24 154
Dose 3 6 94 24 215
Dose 4 15-18 361 179 580
Haemophilus influenzae type b (Hib) 730-92=638
Dose 1 2 38 93
Dose 2 4 66 24 154
Dose 3 6 94 24 215
Dose 4 12-15 361 52 580
Pneumococcal conjugate vaccine (PCV) 730-92=638
Dose 1 2 38 93
Dose 2 4 66 24 154
Dose 3 6 94 24 215
Dose 4 12-15 361 52 580
Polio (IPV) 730-92=638
Dose 1 2 38 93
Dose 2 4 66 24 154
Dose 3 6-18 94 24 580
Measles, mumps, and rubella (MMR) 730-488=242
Dose 1 12-15 361 489
Varicella 730-488=242
Dose 1 12-15 361 489
Maximum Average Number of Days Undervaccinated: = (638 + 160 + 638 + 638 + 638 + 638 + 242 + 242) / 8 vaccines = 479.25
From Glanz et al. 20133 adapted from Luman et al. 20054 and Opel et al. 201131
ACIP=Advisory Committee on Immunization Practices
a Influenza vaccine was not included the analysis because days undervaccinated cannot be calculated with a seasonal vaccine in which children can receive the 
vaccine at varying ages; Hepatitis A vaccine was not included because recommendations are relatively new and the low coverage rate suggests low adherence to the 
recommendations by physicians. 
b  For vaccines administered as combination vaccines (e.g., Pentacel®, Pediarix®, ProQuad®) the components of the combination vaccines were treated individually. 
c  The minimum acceptable interval between doses 2 and 3 was changed from 52 days (per Luman et al. 2005)4 to 38 days because Pediarix® doses may be 
administered in 6-week intervals. 
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Appendix 2.b: Policy changes, vaccine shortages, and brand-specific dosing considerations for assessing under 
vaccination in a retrospective VSD cohort, 2004-2013
Description
Modification to calculating average days 
undervaccinated (ADU)
Policy Changes
Change in recommended age for varicella vaccine In 2007, the recommended age for the varicella 
vaccine changed from 12-18 months to 12-15 
months94 
Prior to the policy change and for three months after, 
count for days under-vaccinated starts when the 
child turns 19 months of age. Starting three months 
after the policy change, count for days under-
vaccinated starts when the child turns 16 months 
of age.
Recommendation for rotavirus vaccination Rotavirus vaccine was universally recommended in 
August, 200695 
Days under-vaccinated for rotavirus vaccine 
incorporated into ADU calculation starting two 
months after the recommendation. At one VSD site, 
rotavirus vaccination introduction occurred much 
later, so days undervaccinated for rotavirus is not 
included until September 2007.
Vaccine Shortages
Pneumococcal vaccine shortage in 2004 Shortage of PCV7 in 2004 led to short-term 
recommendations to delay or not administer 3rd and 
4th doses in children96-98 
Children born January 2004 - May 2004 are not 
penalized for any delay in the 3rd or 4th dose of 
pneumococcal vaccine.
Hib vaccine shortages in 2007-2009 Shortages of Hib vaccines led to short-term 
recommendations to not administer 4th booster 
dose99,100
If a child was age 12-15 months between Dec 18th, 
2007 and July 30th, 2009, he/she is not penalized for 
not receiving 4th dose of Hib.
Brand-specific dosing
Different dosing recommendations for rotavirus 
vaccines
ACIP recommends 2 doses of Rotarix® or 3 doses of 
Rotateq® by age 6 months23
If Rotarix® is administered for the first 2 doses, then a 
3rd dose of rotavirus vaccine is not required.
Different dosing recommendations for Hib vaccines ACIP recommends 2 doses of PedvaxHib® or Comvax® 
or 3 doses of ActHIB® by age 6 months23
If PedvaxHib® or Comvax® is administered for the first 
2 doses, then a 3rd dose of Hib vaccine is not required. 
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Appendix 2.c: Examples of potential survey domains and questions within a survey of parents of 
undervaccinated children.
Example Questions Source/Notes
Survey Domain Assessment of Vaccination Status
Our records indicate that [your child] has not received all of [his/her] recommended vaccines. Is that 
correct?
Our records indicate that [your child] did not receive any vaccines before 6 months of age. Is that correct? Can ask about specific patterns of undervaccination.
Our records indicate that [your child] has not received the measles-mumps-rubella, also called MMR, 
vaccine. Is that correct?
Can ask about specific patterns of undervaccination.
Not counting a dose of Hepatitis B vaccine that [your child] may have received in the hospital after birth, 
has [your child] received any vaccines at any place other than at [MCO]?
Assessment of Reasons for Undervaccination
Introduction: Now I’d like to ask you about times when you decided not to get a vaccination for [your 
child], and the about times when you delayed getting a vaccination for [your child].
From 2009 National Immunization Survey
Has there ever been a time when you refused or decided not to get a vaccination for [your child]? From 2009 National Immunization Survey
Now, has there ever been a time when you delayed or put off getting a vaccination for [your child]? From 2009 National Immunization Survey
Please tell me all the reasons why you refused or delayed getting vaccines for [your child]? Was it 
because…
From 2009 National Immunization Survey; however, this 
level of granularity may not be needed for current survey.
 Your child was ill at the time?
 You have safety or side-effect concerns?
 You heard or read bad things through the media?
 You missed or couldn’t get an appointment?
 You feel that there are too many shots?
 You wonder about the effectiveness of the vaccine?
 You have concerns about cost?
 You have transportation problems?
 Getting vaccines was not convenient?
 You have concerns about autism?
 Any other reason?
Health Care Utilization
Not counting the time in the hospital after [he/she] was born, have you ever taken [your child] to 
someplace other than [MCO] to get health care?
If [your child] had an urgent need for health care, would you take [him/her] to [MCO] to get that care?
Have you ever taken [your child] to an alternative medicine provider, such as a chiropractor, naturalist, 
homeopath, or acupuncturist, when your child was sick?
Child General Health Status
In general, how would you describe [your child’s] health? Would you say [his/her] health is excellent, very 
good, good, fair, or poor?
From National Survey of Children’s Health 2012
Does [your child] need or use more medical care, mental health, or educational services than is usual for 
most children of the same age?
From National Survey of Children’s Health 2012
Is [your child] limited or prevented in any way in [his/her] ability to do the things most children of the 
same age can do?
From National Survey of Children’s Health 2012
Family Characteristics
Parental education level Note that some data regarding child and family will be 
available from electronic health records
Annual family income categories May not be needed
Do you have any health insurance that covers [your child], other than your insurance at [VSD site]?
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Appendix 2.d: Estimated sample sizes for primary data collection across a range of estimated confirmation 
rates and desired confidence interval widths (alpha= 0.05)101,102
Desired confidence interval width
Estimated confirmation rate 0.05 0.075 0.10
10% 138 61 35
20% 246 109 61
30% 323 143 81
40% 369 164 92
50% 384 171 96
60% 369 164 92
70% 323 143 81
80% 246 109 61
90% 138 61 35
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